

## PERSONAL INFORMATION

## Domenico Mavilio



Unit of Clinical and Experimental Immunology (UCEI),  
Department of Medical Biotechnologies and Translational Medicine (BIOMETRA) –  
Medical School of Milan University  
Affiliated Hospital: Humanitas Research Hospital (HRH)  
Via Alessandro Manzoni 113, 20089 Rozzano, Milano, (Italy)

(+39) 02 8224 5157 (Humanitas Research Hospital)  
(+39) 02 5033 0442 (L.I.T.A. – Segrate, Milan)  
Fax: (+39) 02 8224 5191

[✉ domenico.mavilio@unimi.it](mailto:domenico.mavilio@unimi.it)  
[✉ domenico.mavilio@humanitas.it](mailto:domenico.mavilio@humanitas.it)  
[✉ dmavilio@nih.gov](mailto:dmavilio@nih.gov)

<https://www.humanitas-research.org/groups/domenico-mavilio-group/>  
<https://www.unimi.it/en/ugov/person/domenico-mavilio>  
BIOMETRA website: <http://eng.biometra.unimi.it/ecm/home/research/research-areas/clinical-and-experimental-immunology>

Date and Place of birth May 22, 1971, Brindisi, Italy | Nationality Italian

Scopus Author ID 6603439694 | ORCID ID [orcid.org/0000-0001-6147-0952](https://orcid.org/0000-0001-6147-0952)

## EDUCATION/POSITIONS

- |                       |   |
|-----------------------|---|
| 31/03/2017–31/03/2023 | <b>Achievement of the “Idoneità Nazionale a Professore di I Fascia (Eligibility for being recruited as Full Professor).</b><br>Italian Ministry of Education, University and Research (MIUR).                             |
| 04/2016–Present       | <b>Associate Professor of Translational Medicine</b><br>Department of Biomedical Technology and Translational Medicine (BIOMETRA), University of Milan University, Milano (Italy)   |
| 09/06/2014–08/06/2020 | <b>Achievement of the “Idoneità Nazionale a Professore di II Fascia (Eligibility for being recruited as Associate Professor).</b> Italian Ministry of Education, University and Research (MIUR).                          |
| 07/2014–Present       | <b>Special Volunteer/Adjunct Investigator.</b><br>Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD (United States) |
| 10/2012–Present       | <b>Principal and Tenured (Clinical and Research) Investigator. Head of the Unit.</b><br>Unit of Clinical and Experimental Immunology (UCEI), Humanitas Research Hospital (HRH), Milano (Italy)                            |
| 10/2012–03/2016       | <b>Assistant Professor of Translational Medicine</b><br>Department of Biomedical Technology and Translational Medicine (BIOMETRA), Medical School of Milan University, Milano (Italy)                                     |

- 01/2008–09/2012 **Principal and Tenured-Track (Clinical and Research) Investigator. Head of the Unit.**  
Unit of Clinical and Experimental Immunology (UCEI), Humanitas Research Hospital (HRH), Milano (Italy)
- 01/2006–12/2008 **Research Fellow (2006-2007) and Adjunct Investigator (2007/2008), (U.S. Federal Temporary Employee Positions). Group Leader of the Innate Immunity Unit.**  
Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland (United States)
- 13/04/2007 **Ph.D. Program in Clinical Immunology**  
Medical School of University of Genova (Italy)  
Shared PhD program between University of Genova and NIH.
- 2002–2005 **Visiting Fellow. Group Leader of the Innate Immunity Unit.**  
LIR, NIAID, NIH, Bethesda, MD (United States)
- 12/11/2002 **Residency Program. Score: 50/50.**  
Medical School of University of Genova, Department of Internal Medicine, Section of Lung Diseases, Genova (Italy)
- 15/05/1999 **Acquisition of Italian M.D. License. Registered in the county of Milano, Italy with the number 41446.**
- 01/04/1998 **Degree of Medicine. Score 110/110.**  
Medical School of the University of Genova, Genova (Italy)
- 13/07/1990 **Diploma of High School. Score: 55/60.**  
Liceo-Ginnasio Statale “Galileo Galilei”, Monopoli (Bari) (Italy)
- 1985–1988 **Stages in English colleges (Oxford-London). Diploma of “Advanced”.**

## PROFESSIONAL EXPERIENCES

---

- 2008–Present **Head of the Unit, UCEI, HRH, Rozzano (Milano), Italy.**
- 2002–2008 **Research activity as Principal Investigator, LIR, NIAID-NIH (Mentor: Dr. A.S. Fauci). Group Leader of the Innate Immunity Unit.**
- 1998–2002 **Research activity in the Immunopathogenesis Unit, Italian Cancer Scientific Institute Genova, Italy (Mentor: Prof. L. Moretta) and in the Laboratory of Molecular Immunology Department of Experimental Medicine, University of Genova (Mentor: Prof. A. Moretta).**
- 1998–2001 **Clinical Activities in 118/ER unit of Hospital of Lavagna, Genova, Italy**

1999 Achievement of BLS (Basic Life Support) from Italian Resuscitation Council

1995-1998 Internship before as student and then as a resident in the Department of Internal Medicine, Section of Immunologica Diseases, University of Genova (Mentor: Prof. F. Indiveri).

#### PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user  
[Common European Framework of Reference for Languages - Self-assessment grid](#)

#### TEACHING

2008–Present As a Tenured and Principal Investigator and Head of UCEI at HRH, Prof. Mavilio coordinates a research team composed by 1 physician-scientist, 4 staff scientists, 5 Ph.D. students, 1 laboratory manager, 1 bioinformatician and 5 under-graduate students.

2008–Present Coordination of teaching classes and courses of Immunology, Immune-pathology and Translational Medicine in the following graduated programs at University of Milan, Italy where Prof. Mavilio serves as associate professor: 1) School of Medicine; 2) School for Biomedical Laboratory Technicians; 3) School of Biotechnology.

2010–Present Member of the Board of the PhD program of "Experimental Medicine" of University of Milan, Italy.

2010–2014 Member of the Board of the Ph.D. Program of Immunology, Open University, Milton Keynes, London, U.K. Program in partnership with HRH.

2010–2012 Visiting Professor of Immunology at International Medical School of Medicine, University of Milan, Italy.

2010 Visiting Professor of Immunology at Medical School of University of Milan, Italy.

2008 Visiting Professor of Immunology at Medical School of University of Brescia, Italy.

2002–2008 Training of Ph.D. students, M.D. students and technicians enrolled in university programs held within the LIR, NIAID, NIH, Bethesda, MD, USA

**A) Undergraduate students**

- 1) Alessandra Russo:** Master Degree of Cellular and Molecular Biology  
(Corso di Laurea a ciclo unico di Biologia Molecolare della Cellula)  
University of Milan, Italy. Graduated on 18/12/2013 with the score of 106/110.  
Thesis entitled: "*Studio delle varianti di splicing alternativo della molecola di adesione cellulare L1CAM nei tumori umani: espressione e rilevanza funzionale nella modulazione dell'attività anti-tumorale delle cellule Natural Killer*".
- 2) Veronica Zanon:** Master Degree of Medical Biotechnology and Molecular Medicine  
(Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy.  
Graduated on 09/10/2013 with the score of 107/110.  
Thesis entitled: "*Phenotypic and functional characterization of T memory stem cells in bone marrow-transplanted patients: implications for post-transplant immune reconstitution*".
- 3) Max Preti:** Master Degree of Pharmaceutical Biotechnology  
(Corso di Laurea Magistrale in Biotecnologie del Farmaco), University of Milan, Italy  
Graduated on 18/07/2014 with the score of 104/110.  
Thesis entitled: "*Homeostatic migration of peripheral blood CD56<sup>bright</sup> NK cells to human liver NK cells to human liver by CCR5*".
- 4) Federica Portale:** Master Degree of Medical Biotechnology and Molecular Medicine  
(Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy.  
Graduated on 02/10/2014 with the score of 110/110 cum laude.  
Thesis entitled: "*Studio dell'espressione genica nel differenziamento delle cellule T di memoria CD8<sup>pos</sup>*".
- 5) Ferdinando Oriolo:** Master Degree of Medical of Applied and Experimental Biology  
(Corso di Laurea Magistrale), Department of Biology and Biotechnologies University of Pavia, Italy.  
Graduated on 21/09/2015 with the score of 110/110 cum laude.  
Thesis entitled: "*Ruolo del polimorfismo di ApoL1 nella costituzione di cellule reservoir di HIV-1 in podociti umani*".
- 6) Elena Bruni:** Master Degree of Medical Biotechnology and Molecular Medicine  
(Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy.  
Graduated on 05/10/2016 with the score of 110/110.  
Thesis entitled: "*Identification of a novel subset of human intra-epithelial NKp46<sup>+</sup>/Vd1 T cells resident in the intestinal mucosa under homeostatic conditions*".
- 7) Michela Calvi:** Bachelor Degree of Biomedical Technician. University of Milan, Italy.  
Graduated on 28/10/2016 with the score of 110/110 cum laude.  
Thesis entitled: "*Sviluppo di un modello in vivo per lo studio del ruolo di pentraxina 3 (PTX3) nel controllo dell'infezione da Salmonella typhimurium*".
- 8) Arianna Capuccetti:** Master Degree of Medical Biotechnology and Molecular Medicine  
(Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy.  
Graduated on 10/10/2017 with the score of 110/110 cum Laude.  
Thesis entitled: "*The early expansion of alloreactive NKG2A<sup>pos</sup>/CD56<sup>dim</sup>/CD16<sup>pos</sup> lymphocytes after hematopoietic stem cell transplant represents a tool to improve the clinical outcome of patients affected by hematologic malignancies and to disclose the ontogenesis of human NK cells*".
- 9) Michela Calvi:** Master Degree of Medical Biotechnology and Molecular Medicine

(Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy. Graduated on 10/08/2018 with the score of 110/110 cum Laude. Thesis entitled: “*Impact of human cytomegalovirus reactivation on natural killer cell reconstitution and unconventional immunological memory after haploidentical hematopoietic stem cell transplantation*”.

- 10) Federica Sorrentino:** Bachelor Degree of Biomedical Technician. University of Milan, Italy. Graduated on 16/11/2018 with the score of 103/110. Thesis entitled: “*Impiego della citofluorimetria multiparametrica nello studio dei linfociti T gd in pazienti con carcinoma coloretale metastatico*”.
- 11) Gloria Leonardi:** International Medical School, University of Milan. Graduated on 12/07/2019 with the score of 110/110 cum Laude. Thesis entitled: “*The relevance of gd T lymphocytes in liver metastatic colorectal cancer patients*”.
- 12) Gianluca Belloni:** Bachelor Degree of Biomedical Technician. University of Milan, Italy. Graduated on 22/11/2019 with the score of 103/110. Thesis entitled: “*Isolamento delle Endothelial colony-forming cells come strumento per la valutazione dell’attività anti-angiogenica di un inibitore dell’RNA elicasi DDX3*”.
- 13) Valentina Cazzetta:** Master Degree of Medical Biotechnology and Molecular Medicine (Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy. Graduated on 20/02/2020 with the score of 110/110. Thesis entitled: “*Identification of a new Vd2 t cell subset as an alternative source for cancer immunotherapy*”.
- 14) Civanelli Elisa:** Master Degree of Medical Biotechnology and Molecular Medicine (Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy. Graduated on 20/02/2020 with the score of 110/110 cum Laude. Thesis entitled: “*P2X7 mediated senescence in limiting tumoricidal activity of tumor infiltrating lymphocytes*”.
- 15) D’Uonnolo Giulia:** Master Degree of Medical Biotechnology and Molecular Medicine (Corso di Laurea Magistrale), BIOMETRA, University of Milan, Italy. Graduated on 20/02/2020 with the score of 110/110 cum Laude. Thesis entitled: “*Characterization of new ligands for ACKR4*”.
- 16) Roberta Ciceri:** Bachelor Degree of Biomedical Technician. University of Milan, Italy. Graduated on 20/11/2020 with the score of 110/110 cum Laude. Thesis entitled: “*Sviluppo di un protocollo sperimentale di espansione delle cellule T Vδ2 per implementare approcci di immunoterapia cellulare aventi come bersaglio il checkpoint inhibitor NKG2A*”.
- 17) Luca Leoni:** Bachelor Degree of Biomedical Technician. University of Milan, Italy. Graduated on 20/11/2020 with the score of 110/110. Thesis entitled: “*Pandemia da SARS-CoV-2: creazione di una nuova bio-banca come risorsa per applicazioni di ricerca in medicina sperimentale*”.

## B) Ph.D. Students

- 1) Dott. Enrico Brunetta:** Ph.D. Program in “Clinical and Experimental Immunology”. Department of Internal Medicine, School of Medicine, University of Genova, Italy. Completed on 03/02/2012. Thesis entitled: “*Redistribution of pathologic Natural Killer subsets in HIV-1 infection*”
- 2) Dott. Kelly L. Hudspeth:** Ph.D. Program in “Pathology and Experimental

Neuropathology". XXV cycle, BIOMETRA, University of Milan, Italy. Completed on 25/03/2013.  
Thesis entitled: *"The Role of Natural Cytotoxicity Receptors in the Homeostasis and Function of a Newly Discovered Subset of gd T cells"*

- 3) **Dott. Irene Mattiola:** Ph.D. Program in "Pathology and Experimental Neuropathology". XXVI cycle, BIOMETRA, University of Milan, Italy. Completed on 24/01/2013.  
Thesis entitled: *"Cross-talk between human NK cells and macrophages: influence of the tumor-microenvironment"*
- 4) **Dott. Alessandra Roberto:** Ph.D. Program in "Clinical and Experimental Immunology". Open University, Milton Keynes, UK in partnership with HRH, Milan, Italy. Completed on 08/04/2015.  
Thesis entitled: *"Cellular mechanisms of adaptive immune Reconstitution following human bone marrow transplantation"*
- 5) **Dott. Elena Pontarini:** Ph.D. Program in "Clinical and Experimental Immunology". Open University, Milton Keynes, UK in partnership with HRH, Milan, Italy. Completed on 19/05/2016  
Thesis entitled: *"Role of natural killer cells in the Sjogren' Syndrome lymphoneogenesis"*
- 6) **Dott. Veronica Zanon:** Ph.D. Program in "Experimental Medicine and Medical Biotechnologies". XIX cycle, BIOMETRA, University of Milan, Italy. Completed on 16/03/2018  
Thesis entitled: *"Stem cell-like properties of memory T cells in human immune reconstitution"*
- 7) **Dott. Palagano Eleonora:** Ph.D. Program in "Experimental Medicine and Medical Biotechnology". XXX cycle, BIOMETRA, University of Milan, Italy. Completed on 19/02/2018  
Thesis entitled: *"New insights in bone biology from exome sequencing of rare skeletal diseases"*
- 8) **Dott. Ferdinando Oriolo:** Ph.D. Program in "Experimental Medicine and Medical Biotechnology". XXXI cycle, BIOMETRA, University of Milan, Italy. Completed on 29/01/2019  
Thesis entitled: *"Characterization and functional relevance of a newly disclosed subset of NCR<sup>pos</sup> γδ T cells naturally resident in human intestine."*
- 9) **Dott. Elisa Zaghi:** Ph.D. Program in "Clinical and Experimental Immunology". Open University, Milton Keynes, UK in partnership with HRH, Milan, Italy. Completed on 14/07/2020  
Thesis entitled: *"Patterns of immune-reconstitution and immunological memory in elderly patients affected by hematologic malignancies and undergoing haplo-identical hematopoietic stem cell transplantation."*
- 10) **Dott. Elena Bruni:** Ph.D. Program in "Experimental Medicine and Medical Biotechnology". XXXII cycle, BIOMETRA, University of Milan, Italy. Completed on 31/01/2020  
Thesis entitled: *"Immunotherapeutic potential and prognostic relevance of γδ T cell subset inpatients affected"*

by liver metastatic colorectal cancer.”

**11) Dott. Claudia Carezza:** Ph.D. Program in “Experimental Medicine and Medical Biotechnology”.  
XXXIII cycle, BIOMETRA, University of Milan, Italy.  
Currently enrolled in the 4<sup>th</sup> year of the program

**12) Dott. Michela Calvi:** Ph.D. Program in “Experimental Medicine and Medical Biotechnology”.  
XXXIV cycle, BIOMETRA, University of Milan, Italy.  
Currently enrolled in the 3<sup>rd</sup> year of the program

**13) Dott. Assunta Cancellara:** Ph.D. Program in “Experimental Medicine and Medical Biotechnology”.  
XXXV cycle, BIOMETRA, University of Milan, Italy.  
Currently enrolled in the 2<sup>nd</sup> year of the program.

**14) Dott. Sara Franzese:** Ph.D. Program in “Experimental Medicine and Medical Biotechnology”.  
XXXVI cycle, BIOMETRA, University of Milan, Italy.  
Currently enrolled in the 1<sup>st</sup> year of the program.

**15) Dott. Valentina Cazzetta:** Ph.D. Program in “Experimental Medicine and Medical Biotechnology”.  
XXXVI cycle, BIOMETRA, University of Milan, Italy.  
Currently enrolled in the 1<sup>st</sup> year of the program.

#### Acquired skills and techniques

- 1) Management skills as Principal Investigator heading the Unit of Clinical and Experimental Immunology: training of M.D. and Ph.D. students, coordination of projects of Translational Medicine, submission and administration of grants and financial supports for biomedical research, dissemination of experimental results (publication on *peer-review* scientific journals, seminars, lectures, participation at international meetings, international networks of collaborations, organization of meetings and seminars).
- 2) Associate Professor of Immunology, Immunopathology and Translational medicine at the University of Milano, Italy
- 3) Clinical management of patients (Internal Medicine, Lung Diseases, Autoimmune Diseases). Admission of patients affected by autoimmune diseases for projects of translational immunology and medicine.
- 4) Respiratory Physiopathology Techniques (Spirometry, Bronchoscopy, Allergometric Tests).
- 5) Separation of PBMC from peripheral blood and from other biological fluids.
- 6) Long term cell line cultures.
- 7) High efficiency lymphocyte cloning by limit dilutions.
- 8) Molecular and cellular cloning.
- 9) Multicolor Flow Cytometry and Cell Sorting (BD Certified Training Program of FACSAria™ Operator. 02/16-20/2004 S. Jose', California, USA).
- 10) Tests of cell proliferation, apoptosis and cell cytotoxicity.
- 11) Dosage of soluble molecules with immuno-enzymatic methods (E.L.I.S.A.), ELISPOT technique and RT assay.
- 12) Amplification and use of Vaccinia Virus and HIV.
- 13) B-lymphocyte cells transformation in BLCL.
- 14) RT-PCR, Real Time PCR (NIH-FAES Certified Training Program 09/21/2004 - 12/07/2004, Bethesda, MD, USA)
- 15) Microarray Analysis (NIH-FAES Certified Training Program 09/13/2004 – 09/17/2004, Bethesda, MD, USA).
- 16) Confocal Microscopy
- 17) Computer Skills: Microsoft Office, Flow Joe, DIVA, Statview, Crimson, Cricket Graph, Canvas, End Note, Claris Draw, Prism, Adobe Photoshop Illustrator

Memberships of Scientific Societies/Journals

**2005-present:** Society for Natural Immunity.  
**2005-present:** International AIDS Society.  
**2008-present:** Italian Society of Immunology (SIICA).  
**2009-present:** Italian Association of Cell Culture (AICC).  
**2010-present:** Society for Leukocyte Biology (SLB).  
**2010-2015:** Member of the Editorial Board of the Journal of Leukocyte Biology (JLB).  
**2015-2016:** Associate Editor of the Editorial Board of the Journal of Leukocyte Biology (JLB).  
**2015-2018:** Review Editor the Editorial Board of Frontiers in Immunology and Public Health – Section of HIV and AIDS.  
**2016-present:** Deputy Editor of the Editorial Board of the Journal of Leukocyte Biology (JLB) (<http://www.jleukbio.org/site/misc/edboard.xhtml>)  
**2012-present:** Member of the Editorial Board of the Journal of Sexually Transmitted Diseases (<https://www.hindawi.com/journals/jstd/editors/>)  
**2012-present:** Member of the Editorial Board of Biomed Research International (<https://www.hindawi.com/journals/bmri/editors/infectious.diseases/>)  
**2014-2018:** Member of the scientific board of Lymphact (<http://www.lymphact.com>).  
**2016-present:** Associate Editor the Editorial Board of Frontiers in Medicine – Section of Innovative Therapies (<http://journal.frontiersin.org/journal/medicine/section/innovative-therapies>).  
**2017-present:** Member of the International Consortium BEAT-HIV, Philadelphia, PA, USA. ([beat-hiv.org](http://beat-hiv.org))  
**2018-present:** Member of the editorial board of the Journal of Autoimmunity (<https://www.journals.elsevier.com/journal-of-autoimmunity>)  
**01/2019-12/2021:** Elected member of the Council of the Society of Leukocyte Biology. (<https://www.leukocytebiology.org>)

Reviewer (ad hoc)

**a) Scientific Journals:** Trends in Microbiology, Blood, Journal of Infectious Diseases, Clinical Immunology, Journal of Experimental Medicine, AIDS, Journal of Immunology, European Journal of Immunology, PLoS One, PLoS Pathogen, Journal of Hepatology, Immunology Letters, Journal of Leukocyte Biology, European Journal of Cancer, BioMed Central Manuscript, Clinical and Experimental Medicine, Journal of Immunological Methods, Mucosal Immunology, Journal of Rheumatology, Retrovirology, Journal of AIDS, Journal of Virology, PNAS, Scientific Reports, Journal of Autoimmunity, Cellular and Molecular Immunology, Immunology and Cell Biology, Frontiers in Immunology, Oncoimmunology, Oncotarget, Frontiers of Medicine, Journal of Clinical Medicine, Seminars in Immunology, Journal of Clinical Investigation, British Journal of Hematology, Cancer Research, Journal of Hepatology, Liver International, Science Immunology, Nature Immunology, Journal of Clinical Medicine, Cells, Journal for ImmunoTherapy of Cancer, Nature Communications, Cancers, Cell and Tissue Research, Heliyon Cell Press, Seminars in immunopathology

**b) Public Funding Agencies, Charities, Biotech Companies:** Institut National de la Santé et de la Recherche Medicale (INSERM- France), The Business Development and Industrial Partnership Department of Institut Pasteur (DARRI, Paris, France), European School of Molecular Medicine and Structured International Post Doc Program (SEMM-SIPOD), Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy), National Czech Science Foundation of Czech Republic (Prague, Czech Republic), BD Bioscience Immunology (St. Jose, CA, USA), Grants - The Netherlands Organization for Health Research and Development (ZonMw), Veni Program (The Hague, Netherlands), Swiss National Science Foundation (Berne, Switzerland), The French National Research Agency (ANR, Paris, France), Medical Research Council (London, U.K.), Israel Science Foundation (Jerusalem, Israel), National Austrian Science Fund (Vienna, Austria), Swiss Cancer League, Swiss Cancer Research (Bern, Switzerland), The Iceland Research Fund (Reykjavik, Iceland), The Croatian Science Foundation (HRZZ – Zagreb, Croatia), Intramural Research Program of University of Milan (Milan, Italy), Intramural Research Program of Humanitas Research Program, (Milan, Italy).



Research Topics  
 (completed or ongoing)

- 1) Phenotypic, functional and molecular studies of cells from innate immunity during the course of viral (such as HIV-1 and HCMV infection) and non-viral (such as mycobacteria) infections, autoimmune and immuno-mediated diseases.
- 2) Cross-talking between innate immune cells in human physiology and physiopathology.
- 3) Physiopathology of innate immune cells in cancer.
- 4) Phenotypic, functional and molecular characterization of Natural Killer markers in non-human primates.
- 5) Clinical trials evaluating the effect of drugs on immune system.
- 6) Homing of innate immune cells in human tissues.
- 7) Neuro-immune pharmacology of innate immune responses.
- 8) Adoptive cell transfer therapy in vivo (mice models) in tumor disorders.
- 9) Immune-reconstitution in bone marrow transplantation.

## Active Scientific Collaborations

**a) Italy**

- 1) Dr. Emanuela Marcenaro, Department of Experimental Medicine, Medical School, University of Genova (ongoing).
- 2) Prof. Massimo Locati, BIOMETRA, University of Milan (ongoing).
- 3) Dott. Luca Castagna, Unit of Haematology, Humanitas Research Hospital, Milan (ongoing).
- 4) Dott. Alessio Pini Prato, Istituto Giannina Gaslini, Genova (ongoing).
- 5) Dott.ssa Isabella Ceccherini, Istituto Giannina Gaslini, Genova.
- 6) Prof. Guido Torzilli, Department of General Surgery, HUNIMED Medical School, HRH, Rozzano, Milano (ongoing).
- 7) Dr. Antonino Spinelli, Department of General Surgery, HUNIMED Medical School, HRH, Rozzano, Milano (ongoing).
- 8) Dr. Corrado Lodigiani, Thrombosis Centre, HRH, Rozzano, Milan (ongoing).
- 9) Dr. Silvio Danese, Centre for Inflammatory Bowel Diseases. HUNIMED Medical School, HRH, Rozzano, Milano (ongoing).
- 10) Prof. Pietro Invernizzi, Center for Autoimmune Liver Disases, University of Milan-Bicocca, (ongoing).
- 11) Prof. Benedetto Bruno, Università degli Studi di Torino (ongoing).

**b) Abroad**

- 1) Dr. Anthony S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA .
- 2) Dr. Mario Roederer, ImmunoTechnology Section, Vaccinia Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- 3) Dott. Luis J. Montaner, HIV-1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, Pennsylvania, USA (ongoing).
- 5) Prof. Antonio Lanzavecchia, Istituto di Ricerca in Biomedicina, Bellinzona, Switzerland.
- 6) Prof. Bruno Silva Santos, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal (ongoing).
- 7) Dott. Henrique Veiga Fernandes, Immunobiology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.
- 8) Prof. Eric Vivier, Centre d'Immunologie de Marseille-Luminy (CIML) – Inserm, Université de la Méditerranée, Marseille, France.
- 9) Dr. William J. Pavan, Mouse Embryology Section, Genetic Disease Research Branch, National Human Menome Reseach Institute, National Institutes of Health, Bethesda, Maryland, USA.
- 10) Dr. Michele Bombardieri, Centre for Experimental medicine and Rheumatology, Barts and the London School of Medicine and Dentistry, U.K. (ongoing).
- 11) Prof. Juan Salazar, Division of Pediatric Infectious Disease, Connecticut Children's Medical Center, Hartford University, Connecticut, USA.
- 12) Dr. Adriana R. Cruz, Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia (ongoing).
- 13) Prof. Marco Colonna, Department Pathology and Immunology, Washington University, St. Louis, Missouri, USA.
- 14) Prof. Eric M. Gerswin, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA, USA (ongoing).
- 15) Dr. Elizabeth A. Grice, Penn Institute for immunology, University of Pennsylvania, Philadelphia, Pennsylvania, USA) (ongoing).
- 16) Prof. David Price, Chair in Infection and Immunity, Cardiff Institute of Infection &

Immunity, Cardiff Medical School, U.K.

17) Dott. Manfred Bohem, Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. (ongoing).

18) Prof. Pedro Romero and Dr. Camilla Jandus, Ludwig Center for Cancer Research Department of Oncology – Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland (ongoing).

#### Publications a) Articles

- 1) De Maria A., Rusconi F., **Mavilio D.**, Zicari R., Anfossi S., Costa P., Ponte M., Mingari M.C., Moretta L. Functional study of CD3+/CD8+/KIR+ lymphocytes clones and ex-vivo analysis of CD3+/CD8+/KIR+ populations from HIV-1 infected patients under HAART. Volume degli Atti del Congresso “AIDS e Sindromi Correlate”-13° Congresso Nazionale. 95 (1999) - *Monduzzi Editore. Impact Factor: not indexed*
- 2) De Maria A., **Mavilio D.**, Costa P., Dignietti P., Fogli M., Mingari M.C. Multiple HLAclass I specific inhibitory NK receptors expression and IL-4/IL5 production by CD8+ T cell clones in HIV-1 infection. *Immunology Letters 2000 June 1; 72(3): 179-182. Impact Factor: 2.9*
- 3) Gazzola P., **Mavilio D.**, Costa P., Fogli M., Bruzzone B., Icardi G., Primavera A., Cocito L., De Maria A. Possible HCV involvement in acute meningoradiculitis/ polyradiculitis of HIV-1 coinfecting patient. *AIDS 2001 March 1; 15(4): 539-541. Impact Factor: 6.881*
- 4) Costa P., Rusconi S., **Mavilio D.**, Fogli M., Murdaca G., Pende D., Mingari M.C., Galli M., Moretta L., De Maria A. Differential disappearance of inhibitory NK receptors during HAART and possible impairment of HIV-1 specific CD8+ CTL. *AIDS 2001 May 25; 15(8): 965-974. Impact Factor: 6.881*
- 5) De Maria A., Biassoni R., Fogli M., Rizzi M., Cantoni C., Costa P., Conte R., **Mavilio D.**, Cafaro A., Moretta A., Moretta L. Identification, molecular cloning and functional characterization of NKp46 and NKp30 Natural Cytotoxicity Receptors in Macaca Fascicularis NK cells. *European Journal of Immunology 2001 December; 31(12): 3546-56. Impact Factor: 4.99*
- 6) Costa P., Rusconi S., Fogli M., **Mavilio D.**, Murdaca G., Puppo F., Mingari M.C., Galli M., Moretta L., De Maria A. Low expression of inhibitory Natural Killer receptors in CD8 cytolytic T lymphocytes in long term non progressor HIV-1 infected patients. *AIDS 2003 Jan 24; 17(2): 257-60. Impact Factor: 5.521*
- 7) De Maria A., Fogli M., Costa P., Murdaca G., Puppo F., **Mavilio D.**, Moretta A., Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression on natural cytotoxicity receptors (NKp46, NKp30, NKp44). *European Journal of Immunology 2003 September; 33(9): 2410-8. Impact Factor: 4.536*
- 8) **Mavilio D.**\*, J. Benjamin, M. Daucher, G. Lombardo, S. Kottilli, M.A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, and A.S. Fauci. Natural Killer cells in HIV-1 Infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. *Proc Natl Acad Sci U S A. 2003 December 9;100(25):15011-6. Impact Factor: 10.896*
- 9) Vitale M., Carlomagno S., Falco M., Pende D., Romeo E., Rivera P., Chiesa M.D., **Mavilio D.**, Moretta A. Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. *International Immunology 2004 October; 16 (10): 1459-66. Impact Factor: 3.543*
- 10) Gupta N, Arthos J, Khazanie P, Steenbeke TD, Censoplano NM, Chung EA, Cruz CC, Chaikin MA, Daucher M, Kottilli S, **Mavilio D.**, Schuck P, Sun PD, Rabin RL, Radaev S, Van Ryk D, Cicala C, Fauci AS. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. *Virology 2005 Feb 20; 332 (2): 491-7. Impact Factor: 3.08*

- 11) **Mavilio D.\***, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, O'Shea MA, Kinter A, Kovacs C, Moretta A, Fauci AS. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals.  
*Proc Natl Acad Sci U S A. 2005 February 22; 102(8):2886-91. Impact Factor: 10.231*
- 12) **Mavilio D.\***, Benjamin J, Kim D, Lombardo G, Daucher M, Kinter A, Nies-Kraske E, Marcenaro E, Moretta A, Fauci AS. Identification of NKG2A and NKp80 as specific Natural Killer cell markers in rhesus and pig-tailed monkeys.  
*Blood 2005 September 1; 106(5): 1718-1725. Impact Factor: 10.131*
- 13) Fauci A.S., **Mavilio D.**, Kottlil S. NK cells in HIV infection; paradigm for protection or targets for ambush.  
*Nature Review Immunology 2005 November; 5 (11): 835-43. Impact Factor: 30.458*
- 14) **Mavilio D.\***, Lombardo G., Kinter A., Fogli M., La sala A., Ortolano S., Farschi A., Follmann D., Gregg R., Kovacs C., Marcenaro E., Pende D., Moretta A., Fauci A.S. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection.  
*Journal of Experimental Medicine 2006 October 2; 203(10): 2239-2350. Impact Factor: 14.484*
- 15) Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, **Mavilio D**, Barker E. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts.  
*Blood 2007 August 15; 110(4): 1207-1214. Impact Factor: 10.896*
- 16) Fogli M. #, **Mavilio D.\*\***, Brunetta E., Varchetta S., Ata K., Roby G., Kovacs C., Follmann D., Pende D., Ward J., Barker E., Marcenaro E., Moretta A. and Fauci A.S. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.  
*PLoS Pathogens 2008 July 11; 4(7):e1000101. Impact Factor: 9.125*
- 17) Varchetta S., Oliviero B., Donato F., Agnelli F., Rigamonti C., Paudice E., Arosio E., Berra M. Rossi G., Tinelli C., Colombo M., **Mavilio D.** and Mondelli M.U. Prospective study of natural killer cell phenotype in recurrent hepatitis c virus infection following liver transplantation.  
*J. Hepatol. 2009 February; 50(2): 314–322. Impact Factor: 7.818*
- 18) Oliviero B., Varchetta S., Paudice E., Michelone G., Zaramella M., **Mavilio D.**, De Filippi F., Bruno S. and Mondelli M.U. Natural Killer Cell Functional Dichotomy in Chronic Hepatitis B and Chronic Hepatitis C Virus Infections.  
*Gastroenterology 2009 September; 137(3): 1151-1160. Impact Factor: 12.899*
- 19) Brunetta E., Fogli M., Varchetta S, Bozzo L., Hudspeth K.L., Marcenaro E., Moretta A. and **Mavilio D.\***. The decreased expression of Siglec-7 represents an early marker of dysfunctional Natural Killer cell subsets associated with high levels of HIV-1 viremia.  
*Blood 2009 October 29, 114(18): 3822-30. Impact Factor: 10.555*
- 20) Ward J., Davis Z., DeHart J., Zimmerman E., Bosque A., Brunetta E, **Mavilio D.**, Planelles V. and Barker E. HIV-1 Vpr triggers natural killer cell mediated lysis of infected cells through activation of the ATR-mediated DNA damage response.  
*PLoS Pathogens 2009 October; 5(10): e1000613. Impact Factor: 8.978*
- 21) **Mavilio D.** and Mantovani A.  
Infezione ed attivazione paradossa del sistema immunitario dell'infezione da HIV-1.  
*Read Files, 10(5): 1-45. Impact Factor: not indexed (in Italian)*
- 22) Brunetta E., Fogli M., Varchetta S, Bozzo L., Hudspeth K.L., Marcenaro E., Moretta A. and **Mavilio D.\*** Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on Natural Killer cells in patients with HCMV co-infection.  
*AIDS 2010 January 2, 24(1): 27-34. Impact Factor: 6.348*

- 23) De Filippo C., Pini-Prato A., Mattioli G., Avanzini S., Rapuzzi G., Cavalieri D., Di Paola M., Stefanini I., Ceccherini I., **Mavilio D.**, Lionetti P., Jasonni V. Genomics approach to the analysis of bacterial communities dynamics in Hirschsprung's disease-associate enterocolitis: a pilot study.  
*Pediatr Surg Int.* 2010 May;26(5):465-71. **Impact Factor: 1.002**
- 24) Giardino-Torchia M.L., Ciaglia E., Masci A.M., Vitiello L., Fogli M., La Sala A., **Mavilio D.**, and Racioppi L. Dendritic cells/Natural Killer Cross-Talk: a Novel Target for Human Immunodeficiency Virus Type-1 Protease Inhibitors.  
*PLoS One.* 2010 Jun 10;5(6):e11052. **Impact Factor: 4.411**
- 25) Brunetta E., Hudspeth K.L. and **Mavilio D.\***  
Pathologic Natural Killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes.  
*J Leukoc Biol.* 2010 Dec;88(6):1119-30. Review. **Impact Factor: 4.626**
- 26) Gorini S., Callegari G., Romagnoli G., Mammi C., **Mavilio D.**, Rosano G., Fini M., Di Virgilio F., Gulinelli S., Falzoni S., Ferrari D., and La Sala A. ATP secreted by endothelial cells blocks CX3CL1-elicited natural killer cell chemotaxis and cytotoxicity via P2Y11 receptor activation  
*Blood.* 2010 Nov 25;116(22):4492-500. **Impact Factor: 10.558**
- 27) Correia D.V., Fogli M., Hudspeth K.L. Da Silva, M.G., **Mavilio D. #** and Silva-Santos B. **.\*#** Differentiation of human peripheral blood V $\delta$ 1+ T-cells expressing the Natural Cytotoxicity Receptor NKp30 for recognition of lymphoid leukemia cells.  
*Blood* 2011 Jul 28;118(4):992-1001. **Impact Factor: 9.898**
- 28) Mikulak J., Negrini S., Klajn A., D'Alessandro R., **Mavilio D.**, Meldolesi J.  
Dual REST-dependence of L1CAM: from gene expression to alternative splicing governed by Nova2 in neural cells.  
*Journal of Neurochemistry,* 2012 Mar; 120(5):699-709. **Impact Factor: 3.973**
- 29) Hudspeth K., Fogli M., Correia D.V., Mikulak J., Roberto A., Della Bella S., Silva-Santos B. **#** and **Mavilio D.\*\*\*** Engagement of NKp30 on V $\delta$ 1 T-cells induces the production of CCL3, CCL4 and CCL5 and suppresses HIV-1 replication.  
*Blood,* 2012 Apr 26;119(17):4013-6. **Impact Factor: 9.06**
- 30) Cruz A.R., Ramirez L.G., Zuluaga A.V., Pillay A., Abreu C., Valencia C., La Vake C., Cervantes J.L.; Dunham-Ems S., Cartun R., **Mavilio D.**, Radolf J.D. and Salazar J.C. Immune Evasion and Recognition of the Syphilis Spirochete in Blood and Skin of Secondary Syphilis Patients: Two Immunologically Distinct Compartments.  
*PLoS Neglected Tropical Diseases,* 2012 July, 6(7): e1717. **Impact Factor: 4.569**
- 31) Varchetta S., Brunetta E., Roberto A., Mikulak J., Hudspeth K., Mondelli M.U. and **Mavilio D.\***. Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes.  
*PLoS ONE,* 2012 Sept 7;7(9):e45821. **Impact Factor: 3.730**
- 32) Tomasello E., Yessaad N., Gregoire E., Hudspeth K., Luci C., **Mavilio D.**, Jean Hardwigsen J., Vivier E. Mapping of NKp46<sup>+</sup> cells in healthy human lymphoid and non-lymphoid tissues  
*Frontiers in Immunology (NK cell biology),* 2012 Nov 20; 3(344):1-12.  
**Impact Factor: 5.695**
- 33) Lugli E., Gattinoni L, Roberto A., **Mavilio D.**, Price D.A., Restifo N.P. and Roederer M. Identification, isolation and in vitro expansion of human and non-human primate T memory stem cells.  
*Nature Protocols,* 2013 Jan;8(1):33-42. **Impact Factor: 7.782**
- 34) Cappelletti M, Giannelli S., Martinelli A., Cetin I., Colombo E., Calcaterra F., **Mavilio D.** and Della Bella S. Lack of activation of peripheral blood dendritic cells in human pregnancies complicated by intrauterine growth restriction.  
*Placenta,* 2013 Jan;34(1):35-41. **Impact Factor: 3.285**
- 35) Matera I., Musso M., Griseri P., Rusmini M., Di Duca M., So M., **Mavilio D.**, Ravazzolo R., Ceccherini I. and Garcia-Barcelo M. Allele-specific expression at the RET locus in blood and gut tissue of individuals carrying risk alleles for hirschsprung disease.

- Human Mutation*, 2013 May; 34(5):754-62. **Impact Factor: 5.050**
- 36) Varchetta S., Oliviero B., **Mavilio D.**, Mondelli M.U. Different combinations of cytokines and activating receptor stimuli are required for human Natural Killer cell functional diversity.  
*Cytokine*. 2013 Apr;62(1):58-63. **Impact Factor: 2.874**
- 37) Rusmini M., Griseri P., Lantieri F., Matera I., Hudspeth K.L., Roberto A., Mikulak J., Avanzini S., Rossi V., Mattioli G., Jasonni V., Ravazzolo R., Pavan W.J., Pini-Prato A., Ceccherini I. and **Mavilio D\***. Induction of RET dependent and independent pro-inflammatory programs in human peripheral blood mononuclear cells from Hirschsprung patients  
*PLoS ONE*, 2013. March 18;8(3):e59006. **Impact Factor: 3.534**
- 38) Hudspeth K., Dilva-Santos B. and **Mavilio D.\***  
Natural Cytotoxicity Receptors: broader expression patterns and function in innate and adaptive immune cells.  
*Frontiers in Immunology (NK cell biology)*, March 2013; 4:69. **Impact Factor: 5.695**
- 39) Villa M., Black S., Groth N., Rothman K.J., Apolone G., Weiss N.S., Aquino I., Boldori L., Caramaschi F., Gattinoni A., Malchiodi G., Crucitti A., Della Cioppa G., Scarpini E., **Mavilio D.** and Mannino S. Safety of MF59®-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Non-Adjuvanted Influenza Vaccine in Northern Italy  
*American Journal of Epidemiology*, 2013;178(7):1139–1145. **Impact Factor: 4.975**
- 40) **Mavilio D.**, Galluzzi L, Lugli E. Novel multifunctional antibody approved for the treatment of breast cancer  
*Oncimmunology*. 2013 Mar 1;2(3):e24567. **Impact Factor: 6.283**
- 41) Colombo E, Calcaterra F, Cappelletti M, **Mavilio D.**, Della Bella S. Comparison of Fibronectin and Collagen in Supporting the Isolation and Expansion of Endothelial Progenitor Cells from Human Adult Peripheral Blood.  
*PLoS One*. 2013 Jun 18;8(6):e66734. **Impact Factor: 3.534**
- 42) Hudspeth K., Pontarini E., Tentorio P., Cimino M.M., Donadon M., Torzilli G., Lugli E., Della Bella S., Gershwin M.E. and **Mavilio D.\*** The Role of Natural Killer Cells in Autoimmune Liver Disease: A Comprehensive Review  
*Journal of Autoimmunity*, November 2013, 46 (2013) 55e65. **Impact Factor: 7.018**
- 43) **Mavilio D.**, Lugli E. Inhibiting the inhibitors: Checkpoints blockade in solid tumors.  
*Oncimmunology*. 2013 Sep 1;2(9):e26535. *Epub* 2013 Sep 26. **Impact Factor: 6.283**
- 44) Pini Prato A., Rossi V., Mosconi M., Holm C, Lantieri F., Griseri P, Ceccherini I., **Mavilio D.**, Jasonni V., Tuo G., Derchi M, Marasini M., Magnano G, Granata C., Ghiggeri G., Priolo E., Sposetti L., Porcu A., Buffa P. and Mattioli G. A prospective observational study of associated anomalies in Hirschsprung's disease  
*Orphanet Journal of Rare Diseases*. 2013 Nov 23;8(1):184. **Impact Factor: 3.958**
- 45) Varchetta S., Lusso P., Hudspeth K., Mikulak J., Mele D, Paolucci S., Cimbri R., Malnati M., Riva A. , Maserati R., Mondelli M.U. and **Mavilio D.\*** Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4<sup>pos</sup> T cells and macrophages  
*Retrovirology*. 2013 Dec 13;10(1):154. **Impact Factor: 4.767**
- 46) Della Bella S. and **Mavilio D.\*** IFN-gamma: a Janus-faced cytokine in dendritic cell programming.  
*J Leukoc Biol*. 2014 95:6-8. **Impact Factor: 4.289**
- 47) Calcaterra F., Taddeo A., Colombo E., Cappelletti M., Martinelli A., Calabrese S., **Mavilio D.**, Cetin I., and Della Bella S. Reduction of maternal circulating endothelial progenitor cells in human pregnancies with intrauterine growth restriction.  
*Placenta* 2014 Jul;35(7):431-6. **Impact Factor: 2.710**
- 48) Rusmini M., Griseri P., Matera I., Pontarini E., Ravazzolo R., **Mavilio D.#** and Ceccherini I.# Expression variability and function of the RET gene in adult peripheral blood mononuclear cells  
*Journal of Cellular Physiology* 2014 Dec;229(12):2027-37. **Impact Factor: 3.839**

- 49) Lugli E. and **Mavilio D.**\* NK cell immune activation in HIV-1 infection: flipping the bad and good side of the same coin.  
*J Leukoc Biol.* 2014 Jul;96(1):1-3. **Impact Factor: 4.289**
- 50) Khan MW, Curbishley SM, Chen HC, Thomas AD, Pircher H, **Mavilio D**, Steven NM, Eberl M, Moser B. Expanded Human Blood-Derived  $\gamma\delta$ T Cells Display Potent Antigen-Presentation Functions.  
*Frontiers in Immunology (NK cell biology)*, 2014 Jul 23;5:344. **Impact Factor: 5.695**
- 51) Mikulak J, Bozzo L, Roberto A, Pontarini E, Tentorio P, Hudspeth K, Lugli E, **Mavilio D.** \* Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor.  
*Journal of Immunology* 2014 Sep 15;193(6):2792-800. **Impact Factor: 4.922**
- 52) Lugli E, Marcenaro E, **Mavilio D.**\* NK Cell Subset Redistribution during the Course of Viral Infections.  
*Frontiers in Immunology (NK cell biology)*, 2014 Aug 14; 5:390. **Impact Factor: 5.695**
- 53) Kepp O., Senovilla L., Vitale I., Vacchelli E., Adjemian S., Agostinis P., Apetoh L., Aranda F., Barnaba V., Bloy N., Bracci L., Breckpot K., Brough D., Buqué A., Castro M.G., Cirone M., Colombo M.I., Cremer I., Demaria S., Dini L., Eliopoulos A., Faggioni A., Formenti S.C., Fučíková J., Gabriele L., Gaipf U.S., Galon J., Garg A., Ghiringhelli F., Giese N.A., Guo Z.S., Hemminki A., Herrmann M., Hodge J.W., Holdenrieder S., Honeychurch S., Hu H.M., Huang X, Illidge T.M., Kono K., Korbelik M., Krysko D.V., Loi S., Lowenstein P.R., Lugli E., Ma Y., Madeo F., Manfredi A.A., Martins I., Matzinger P., **Mavilio D.**, Menger L., Merendino N., Michaud M., Mignot G., Mossman K.L., Multhoff G., Oehler R., Palombo F., Panaretakis T., Pol J., Proietti E., Ricci J.E., Riganti C., Rovere-Querini P., Rubartelli A., Sistigu A., Smyth M.J., Sonnemann J., Spisek R., Stagg J., Sukkurwala A.Q., Tartour E., Thorburn A., Thorne S.H., Vandenabeele P., Velotti F, Workenhe S.T., Yang H., Zong W.X., Zitvogel L., Kroemer G. and Galluzzi L. Consensus guidelines for the detection of immunogenic cell death *Oncoimmunology*. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct.  
**Impact Factor: 6.266**
- 54) Dieli F. and **Mavilio D.**\* Activation, functions and generation of immunological memory in  $\gamma\delta$ T lymphocytes: lessons from non-human primates  
*J Leukoc Biol.* 2014 Dec;96(6):948-50 **Impact Factor: 4.289**
- 55) Galluzzi L., Vacchelli E., Bravo-San Pedro J.M., Buqué A., Senovilla L., Baracco E.E., Bloy N., Castoldi F., Abastado J.P., Agostinis P., Apte R.N., Aranda F., Ayyoub M., Beckhove P., Blay J.Y, Bracci L., Caignard A., Castelli C., Cavallo F, Celis E., Cerundolo V., Clayton A., Colombo M.P., Coussens L., Dhodapkar M.V., Eggermont A.M., Fearon D.T., Fridman W.H., Fučíková J., Gabrilovich D.I., Galon J., Garg A., Ghiringhelli F., Giaccone G., Gilboa E., Gnjatic S., Hoos A., Hosmalin A., Jäger D., Kalinski P., Kärre K.48, Kepp O., Kiessling R., Kirkwood J.M., Klein E., Knuth A., Lewis C.E, Liblau R., Lotze M.T., Lugli E., Mach J.P., Mattei F., **Mavilio D.**, Melero I., Melief C.J., Middendorf E.A., Moretta L., Odunsi A., Okada H., Palucka A.K., Peter M.E., Pienta K.J., Porgador A., Prendergast G.C, Rabinovich G.A., Restifo N.P., Rizvi N., Sautès-Fridman C., Schreiber H., Seliger B., Shiku H., Silva-Santos B., Smyth M.J., Speiser D.E., Spisek R., Srivastava P.K., Talmadge J.E., Tartour E., Van Der Burg S.H., Van Den Eynde B.J., Vile R., Wagner H., Weber J.S., Whiteside L., Wolchok J.D. Classification of current anticancer immunotherapies  
*Oncotarget.* 2014 Dec 30;5(24):12472-508. **Impact Factor: 6.359**
- 56) Cappelletti M., Presicce P., Calcaterra F., **Mavilio D.**# and Della Bella S. # Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins.  
*Immunology.* 2015 Apr;144(4):661-7. **Impact Factor: 4.078**
- 57) Roberto A., Castagna L., Gandolfi S., Zanon V., Bramanti S., Sarina B., Crocchiolo R., Todisco E., Carlo-Stella C., Tentorio P., Timofeeva I., Santoro A., Della Bella S., Roederer M., **Mavilio D.** \*\* and Lugli E. \*\* B-cell reconstitution after unmanipulated

- haploidentical bone marrow transplantation recapitulates B-cell lymphopoiesis  
*Bone Marrow Transplantation*. 2015 Feb;50(2):317-9. **Impact Factor: 3.636**
- 58) Pontarini E., Fabris M., Quartuccio L., Cappelletti M., Calcaterra F., Roberto A., Curcio F., **Mavilio D.** \*\*, Silvia Della Bella<sup>#</sup> and De Vita S. Treatment with belimumab restores B cell subsets and their expression of BAFF receptor in patients with primary Sjogren's syndrome  
*Rheumatology* 2015 Aug;54(8):1429-34. **Impact Factor: 4.524**
- 59) Crocchiolo R., Bramanti S., Vai A., Sarina B., Mineri R., Casari R., Tordato F., Mauro E., Timofeeva I., Lugli E., Mavilio D., Carlo-Stella C., Santoro A. and Castagna L. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as GVHD prophylaxis  
*Transplant Infectious Disease*, 2015 Apr;17(2):242-9. **Impact Factor: 1.459**
- 60) Roberto A., Castagna L., Zanon V., Bramanti S., Crocchiolo R., McLaren J.E., Gandolfi S., Tentorio P., Sarina B., Timofeeva I., Santoro A., Carlo-Stella C., Bruno B., Carniti C., Corradini P., Gostick E., Ladell K., Price D.A., Roederer M., **Mavilio D.** \*\* and Lugli E.<sup>#</sup>. "Role of naïve-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation"  
*Blood*. 2015 Apr 30;125(18):2855-64. **Impact Factor: 11.841**
- 61) Mattioli I., Pesant M., Tentorio P., Molgora M., Marcenaro E., Lugli E., Locati M.<sup>\*\*</sup> and **Mavilio D.** \*\* Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1 $\alpha$ , IFN- $\gamma$  and IL-15 pathways  
*Journal of Immunology* 2015 Sep 15;195(6):2818-28. **Impact Factor: 4.985**
- 62) Tomescu C., **Mavilio D.** and Montaner L.J.  
 Lysis of HIV-1 infected autologous CD4<sup>+</sup> primary T cells by interferon-alpha activated NK cells Requires NKp46 and NKG2D.  
*AIDS* 2015 Sept. 10; 29(14): 1767–1773. **Impact Factor: 4.407**
- 63) Hudspeth K, Donadon M., Cimino M., Pontarini E., Tentorio P., Preti M., Hong M., Bertoletti A., Biciato S., Invernizzi P., Lugli E., Torzilli G., Gershwin M.E. \*, **Mavilio D.** \* Human liver-resident CD56<sup>bright</sup>/CD16<sup>neg</sup> NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.  
*J Autoimmun.* 2016 Jan;66:40-50. **Impact Factor: 7.760**
- 64) Alfano M., Cinque P., Giusti G.<sup>3</sup>, Proietti S., Nebuloni M., Danese S., D'Alessio S., Genua M., Portale F., Lo Porto M., Singhal P.C., Rastaldi M.P., Saleem M.A., **Mavilio D.** \*\* and Mikulak J. \*\* Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes  
*Scientific Reports* 2015 Sep 18;5:13647. **Impact Factor: 5.228**
- 65) Cappelletti M., Ferrazzi E., Della Bella S., **Mavilio D.** and Divanovic S.  
 Inflammation and preterm birth  
*J Leukoc Biol.* January 2016; 99(1):67-78. **Impact Factor: 4.165**
- 66) Pilipow K., Roberto A., Roederer M., Waldmann T.A., **Mavilio D.**, Lugli E.  
 IL-15 and T cell stemness in T cell-based cancer immunotherapy  
*Cancer Res.* 2015 Dec 15;75(24):5187-93. **Impact Factor: 8.556**
- 67) Della Bella S. \*\* and **Mavilio D.** \*\* "Senescent angiogenic T cells: using CD28 makes the difference in endothelial homeostasis"  
*J Leukoc Biol.* March 2016; 99:399-401. **Impact Factor: 4.018**
- 68) Al Malki M.M., Horowitz M., Handgretinger R., Leung W., Roy D.C., Huang X.J., Fuchs E., Locatelli F., Blaise D., Mineishi S., Martelli M., Miller J., June C., Ai H.S., Luznik L., **Mavilio D.**, Lugli E., Van Den Brink M.R.M., Champlin R.E., Ciurea S.O. Proceedings from the Second Haploidentical Stem-cell Transplantation Symposium – Haplo 2014, San Francisco, California, December 4, 2014  
*Biol Blood Marrow Transplant.* 2016 Apr;22(4):594-604 2016. **Impact Factor: 4.704**

- 69) Lugli E.\*\*, Hudspeth K.\*\*, Roberto A. and **Mavilio D.\*\***  
Tissue-resident and memory properties of human T-cell and NK-cell subsets.  
*European Journal of Immunology*, 2016 Aug;46(8):1809-17. **Impact Factor: 4.227**
- 70) Waggoner S.N. and **Mavilio D.\*** "Natural killer cells "strike" a new cord  
*J Leukoc Biol.* 2016 Sep;100(3):449-51. **Impact Factor: 4.018**
- 71) Mikulak J.\*, Oriolo F., Portale F., Tentorio P., Lan X., Saleem M.A., Skorecki K., Singhal P.C. and **Mavilio D.\*** Impact of APOL1 polymorphism and IL-1 $\alpha$  priming in the entry and persistence of HIV-1 in human podocytes.  
*Retrovirology*, 2016 Sept. 6,13(63). **Impact Factor: 3.897**
- 72) Castagna L. and **Mavilio D.\***  
Re-discovering NK cell allo-reactivity in the therapy of solid tumors  
*Journal for ImmunoTherapy of Cancer*, 2016 Sep 20;4:54.  
**Impact Factor: 8.374**
- 73) Calcaterra F, Brambilla L., Colombo E., Turlaki A., Veraldi S., Carezza C., **Mavilio D# and Della Bella S. \*\***. Increased frequency and vasculogenic potential of endothelial colony-forming cells in patients with Kaposi's sarcoma.  
*Journal of Investigative Dermatology*, (2017) 137(7), 1533-1540.  
**Impact Factor: 6.448**
- 74) Mikulak J., Di Vito C., Zaghi E and **Mavilio D.\***  
Host immune responses in HIV-1 infection: the emerging pathogenic role of Siglecs and their clinical correlates  
*Frontiers in Immunology (NK cell biology)*, 2017 Mar 23; 8:314. **Impact Factor: 5.511**
- 75) Donadon M., Hudspeth K, Cimino M., Di Tommaso L., Preti M., Tentorio P., Roncalli M., **Mavilio D.\*\*** and Torzilli G.\*\*  
Increased infiltration of Natural Killer and T cells in colorectal liver metastases improves patient overall survival."  
*Journal of Gastrointestinal Surgery* 2017 J Aug;21(8):1226-1236. **Impact Factor: 2.813**
- 76) Zanon V., Pilipow K., Scamardella E., De Paoli F., De Simone G., Martinez Usatorre A., Romero P., **Mavilio D.**, Roberto A. and Lugli E.  
Curtailed T-cell activation curbs effector differentiation and generates CD8+ T cells with a naturally-occurring memory stem cell phenotype  
*Eur. J. Immunol.* 2017 Sep;47(9):1468-1476. **Impact Factor: 4.248**
- 77) TrabANELLI S., Chevalier M., Usatorre A.M., Gomez-Cadena A., Salomé B., Lecciso M., Salvestrini V., Verdeil G., Racle J., Papayannidis C., Morita H, Pizzitola I., Grandclement C., Bohner P., Bruni E., Girotra M., Pallavi R., Falvo P., Leibundgut E., Baerlocher G., Carlo-Stella C., Taurino D., Santoro A., Spinelli O., Rambaldi A., Giarin E., Basso G., Tresoldi C., Ciceri F., Gfeller D., Akdis A., Mazzarella L., Minucci S., Pelicci P., Marcenaro E., McKenzie A., Vanhecke D., Coukos G., **Mavilio D.**, Curti A., Derrel and Jandus C.  
Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.  
*Nature Communication.* 2017 Sep 19;8(1):593. **Impact Factor: 12.353**
- 78) Ungaro F., Tacconi C., Massimino L., Corsetto P.A., Correale C., Fonteyne P., Piontini A., Garzarelli V., Calcaterra F., Della Bella S., Spinelli A., Carvello M., Rizzo A.M., Vetrano S., Petti L., Fiorino G., Furfaro F., **Mavilio D.**, Maddipati K.R., Malesci A., Peyrin-Biroulet L., D'Alessio S. and Danese S.  
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice.  
*Gastroenterology* 2017 Nov; 153(5):1363-1377. **Impact Factor: 20.773**
- 79) Mikulak J., Oriolo F., Zaghi E., Di Vito C. and **Mavilio D.\***  
Natural Killer cells in HIV-1 infection and therapy  
*AIDS* 2017 Nov 13;31(17):2317-2330. **Impact Factor: 4.914**



- 80) Trabanelli S., Gomez-Cadena A., Salomé B., Michaud K., **Mavilio D.**, Landis B.N., Jandus P. and Jandus C.  
Human Innate Lymphoid Cells (ILCs): Towards a uniform immune-phenotyping.  
*Cytometry B Clin Cytom.* 2017 Dec 15 [Epub ahead of print]. **Impact Factor: 2.757**
- 81) Al Malki M., Jones R., Ma Q., Lee D., Reisner Y., Miller J.S., Lang P., Hongeng S., Hari P., Strober P., Yu J., Maziarz R., **Mavilio D.**, Roy D.C., Bonini C., Champlin R.E., Fuchs E. J. and Ciurea S.O.  
 Proceedings from the Fourth Haploidentical Stem Cell Transplantation Symposium – HAPLO2016, San Diego, California, December 1, 2016  
*Biol Blood Marrow Transplant.* 2018 Jan 12. pii: S1083-8791(18)30023-5. doi: 10.1016/j.bbmt.2018.01.008. [Epub ahead of print] Review. **Impact Factor: 3.599**
- 82) Roberto A, Di Vito C., Zaghi E., Mazza E.M.C., Capucetti A., Calvi M., Tentorio P., Zanon V., Sarina B., Mariotti J., Bramanti S., Tenedini E., Tagliafico E., Biciato S., Santoro A., Roederer M., Marcenaro E., Castagna L., Lugli E<sup>\*\*</sup>. and **Mavilio D<sup>\*\*</sup>**.  
 The early expansion of anergic NKG2A<sup>pos</sup>/CD56<sup>dim</sup>/CD16<sup>neg</sup> natural killer represents a therapeutic target in haploidentical haematopoietic stem cell transplantation  
*Haematologica.* 2018 Aug;103(8):1390-1402. **Impact Factor: 7.570**
- 83) Molgora M., Supino D., **Mavilio D.**, Santoni A., Moretta L., Mantovani A. and Garlanda C.  
 The yin-yang of the interaction between myelomonocytic cells and NK cells.  
*Scand J Immunol.* 2018 Sep;88(3): e12705. **Impact Factor: 2.563**
- 84) Brummelman J., Mazza E.M.C., Alvisi G., Colombo F.S., Grilli A., Mikulak J., **Mavilio D.**, Alloisio M., Ferrari F., Lopci E., Novellis P., Veronesi G. and Lugli E.  
 High-1 dimensional single cell analysis identifies stem-like cytotoxic CD8+ 2 T cells infiltrating human tumors.  
*J Exp Med.* 2018 Oct 1; 215(10):2520-2535. **Impact Factor: 10.892**
- 85) Pontarini<sup>#</sup>, Lucchesi D. <sup>#</sup>, Fossati-Jimack L., Coleby R., Tentorio P., Croia C., Bombardieri M<sup>#</sup> and **Mavilio D. <sup>\*\*</sup>**  
 NK cell recruitment in salivary glands provides early viral control but is dispensable for tertiary lymphoid structure formation.  
*J Leukoc Biol.* 2019 Mar;105(3):589-602. **Impact Factor: 4.012**
- 86) Zaghi E., Calvi M., Marcenaro E., **Mavilio D.** and Di Vito C.  
 Targeting NKG2A to elucidate Natural Killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy  
*J Leukoc Biol.* 2019 2019 Jun;105(6):1243-1251. **Impact Factor: 4.012**
- 87) Mikulak J., Bruni E., Oriolo F., Di Vito C. and **Mavilio D<sup>\*</sup>**.  
 Hepatic Natural Killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology.  
*Frontiers in Immunology (Section of NK and Innate Lymphoid Cell Biology)* 2019 Apr 30;10: 946. **Impact Factor: 4.716**
- 88) Mikulak J., Dieli F. <sup>#</sup> and **Mavilio D. <sup>\*\*</sup>**  
 Are human V $\alpha$ 2<sup>pos</sup> T cells really resistant to aging and Human Cytomegalovirus Infection?  
*Ebiomedicine*, 2019 May; 43:30. **Impact Factor: 6.680**
- 89) Di Vito C., Mikulak J., Zaghi E., Pesce S, Marcenaro E. <sup>\*\*</sup> and **Mavilio D. <sup>\*\*</sup>**  
 NK cells to cure cancer  
*Seminars in Immunology*, 2019 Feb;41:101272. **Impact Factor: 7.358**
- 90) Della Bella S. <sup>\*\*</sup>, Calcaterra F.<sup>#</sup>, Bacci M., Carezza C., Pandolfo C., Ferrazzi P., Uva P., Pagani M., Lodigiani C.<sup>#</sup> and **Mavilio D.<sup>\*\*</sup>**  
 Pathologic up-regulation of TNFSF15-TNFRSF25 axis sustains endothelial dysfunction in unprovoked venous thromboembolism.  
*Cardiovascular Research* 2020 Mar 1;116(3):698-707. **Impact Factor: 7.014**

- 91) Carenza C. #, Calcaterra D.#, Oriolo F., Di Vito C., Ubezio M., Della Porta M.G., **Mavilio D.#\*** and Della Bella S.#\*.  
Costimulatory molecules and immune checkpoints are differentially expressed on different subsets of dendritic cells.  
*Frontiers in Immunology* 2019 (section of Antigen Presenting Cell Biology)  
2019, Jun 11; 10:1325. **Impact Factor: 4.716**
- 92) Di Vito C., Mikulak J. and **Mavilio D.\***.  
On the way to become a Natural Killer cell.  
*Frontiers in Immunology* (Section of NK and Innate Lymphoid Cell Biology)  
2019. August, 2; 10:1812. **Impact Factor: 4.716**
- 93) Pini Prato A., Bartow-McKenney C. 3, Hudspeth K., Mosconi M., Rossi V., Avanzini S., Faticato M.G., Ceccherini I., Lantieri F., Mattioli G., Larson D., Pavan W., De Filippo C., Di Paola M., **Mavilio D.** and Cavalieri D.  
A Metagenomics Study on Hirschsprung's Disease Associated Enterocolitis: Biodiversity and Gut Microbial Homeostasis Depend on Resection Length and Patient's Clinical History.  
*Frontiers in Pediatrics* (Section of Pediatric Infectious Diseases)  
2019. August, 9; 7:329. **Impact Factor: 2.349**
- 94) Pesce S., Belgrano V., Greppi M., Carlomagno S., Squillaro M., Barla A., Della Chiesa M., Di Domenico S., **Mavilio D.**, Moretta L., Candiani S, Sivori S., De Cian F., and Marcenaro E.  
Different features of tumor-associated NK cells in patients with low- or high-grade peritoneal carcinomatosis.  
*Frontiers in Immunology* (Section of NK and Innate Lymphoid Cell Biology)  
2019 August, 21; 10:1963. **Impact Factor: 4.716**
- 95) Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D., Vierling J., Adams D, Alpini G., Asurmendi J.B., Beuers U., Björnsson E., Bowlus C.L., Carbone M., Chazouillères O., Dalekos G, De Gottardi A., Harada K, Hirschfield G., Invernizzi P., Jones D., Krawitt E., Lanzavecchia A., Lian Z-X, Ma X., Manns M, **Mavilio D.**, Quigley E., Sallusto F., Shimoda S., Strazzabosco M., Swain M., Tanaka A., Trauner M., Tsuneyama K., Zigmond E and Gershwin M.E.  
The Challenges of Primary Biliary Cholangitis: What is new and what needs to be done  
*J Autoimmun.* 2019 Dec; 105:102328. **Impact Factor: 7.543**
- 96) Salomé B., Gomez-Cadena A., Loyon R., Suffiotti M., Salvestrini V., Wyss T., Vanoni G., Ruan D.F, Rossi M., Tozzo A., Tentorio P., Bruni E., Riether C., Jacobsen E.M., Jandus P., Conrad C., Hoening M., Schulz A., Michaud K.<sup>16</sup>, Della Porta M.G., Salvatore S., Ho P.C., Gfeller D., Ochsenbein A., **Mavilio D.**, Curti A., Marcenaro E., Steinle A., Horowitz A., Romero P., TrabANELLI S. and Jandus C.  
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML  
*Blood Advances* 2019 Nov 26;3(22):3674-3687. **Impact Factor: 4.584**
- 97) De Simone G., Mazza E.M.C., Cassotta A., Davydov A.N., Kuka M., Zanon V., De Paoli F., Scamardella E., Metsger M., Roberto A., Pilipow K., Colombo F.S., Tenedini E., Tagliafico E., Gattinoni L., **Mavilio D.**, Peano C., Price D.A., Singh S.P., Farber J.M., Serra V., Cucca F., Ferrari F., Orrù V., Fiorillo E., Iannacone M., Chudakov D.M., Sallusto F. and Lugli E.  
CXCR3 identifies human naive CD8<sup>+</sup> T cells with enhanced effector differentiation potential  
*Journal of Immunology* 2019 Dec 15;203(12):3179-3189. **Impact Factor: 4.886**
- 98) Mikulak J.#, Oriolo F.#, Bruni E., Roberto A., Colombo F.S., Villa A., Bosticardo M., Bortolomai I., Lo Presti E., Meraviglia S., Dieli F., Vetrano S., Danese S., Della Bella S., Carvello M.M., Sacchi M., Cugini G., Colombo G., Klinger M., Spaggiari P., Roncalli M., Prinz I., Ravens S., Di Lorenzo B., Marcenaro E., Silva-Santos B., Spinelli A. and **Mavilio D.\***  
NKp46-expressing human gut-resident intraepithelial V $\alpha$ 1 T cell subpopulation exhibits

- high anti-tumor activity against colorectal cancer  
*JCI Insight* 2019 Dec 19;4(24). **Impact Factor: 6.205**
- 99)** Zaghi E., Calvi M., Di Vito C. and **Mavilio D.\***  
 Innate immune responses in the outcome of haploidentical hematopoietic stem cell transplantation to cure hematologic malignancies.  
*Frontiers in Immunology (Section of Alloimmunity and Transplantation)*  
 2019 Nov 28;10:2794. **Impact Factor: 5.085**
- 100)** Bruni E., Cazzetta V., Donadon M., Cimino M., Torzilli G., Spata G., Leonardi G., Dieli F., Mikulak J.\*# and **Mavilio D.\*#**  
 Chemotherapy accelerates immune-senescence and functional impairments of circulating V $\delta$ 2<sup>pos</sup> T cells in elderly patients affected by liver metastatic colorectal cancer.  
*Journal for ImmunoTherapy of Cancer*, 2019 Dec 11;7(1):347. **Impact Factor: 9.913**
- 101)** Cimino M.M., Donadon M., Giudici S., Sacerdote C., Di Tommaso L., Roncalli M., **Mavilio D.**, Hudspeth K. and Torzilli G.  
 Peri-tumoural CD3+ Inflammation and Neutrophil-to-Lymphocyte Ratio Predict Overall Survival in Patients Affected by Colorectal Liver Metastases Treated with Surgery  
*J Gastrointest Surg.* 2019 2020 May;24(5):1061-1070. **Impact Factor: 2.573**
- 102)** Mariotti J., Taurino D., Marino F., Bramanti S., Sarina B., Morabito L., De Philippis C.1, Vito C., **Mavilio D.**, Carlo-Stella C., Della Porta M., Santoro A., and Castagna L.  
 Pre-Transplant Active Disease Status and HLA class II Mismatching are Associated with increased incidence and severity of Cytokine Release Syndrome after Haploidentical Transplantation with Post-Transplant Cyclophosphamide  
*Cancer Medicine* 2020 Jan;9(1):52-61. **Impact Factor: 3.491**
- 103)** Locarno C.V., Simonelli M., Carenza C., Capucetti A., Stanzani S., Lorenzi E., Persico P., Della Bella S., Passoni L., **Mavilio D.**, Bonecchi R., Locati M. and Savino B.  
 Role of myeloid cells in the immunosuppressive microenvironment in gliomas  
*Immunobiology* 2020 Jan;225(1):151853. **Impact Factor: 2.788**
- 104)** Mikulak J., Di Vito C. and **Mavilio D.\***  
 HIV-1-induced inflammation shapes innate immunity and induces adaptive traits for NK cells.  
*Nature Immunology* 2020 Mar;21(3):245-247. **Impact Factor: 20.479**
- 105)** Lia G., Di Vito C., Cerrano M., Brunello L., Calcaterra F., Tapparo M., Giaccone L., **Mavilio D.** and Bruno B.  
 Extracellular vesicles after allogeneic hematopoietic stem cell transplantation: emerging role as biomarkers of inflammatory complications and Graft-vs-Host Disease  
*Frontiers in Immunology (Section of Alloimmunity and Transplantation)*  
 2020 Mar 20;11:422. **Impact Factor: 5.085**
- 106)** Mariotti J., Raiola A.M., Evangelista A., Carella A.M., Martino M., Patriarca F., Risitano A., Bramanti S., Busca A., Giaccone L., Brunello L., Merla E., Savino L., Lotetra B., Console G., Fanin R., Sperotto A., Marano L., Marotta S., Frieri C., Sica S., Chiusolo P., Harbi S., Furst S., Santoro A., Bacigalupo A., Blaise B., Angelucci E., **Mavilio D.#**, Castagna L.\*\* and Bruno B.#  
 Impact of Donor Age and Kinship on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide  
*Blood Advances* 2020 4(16): 3900–3912. **Impact Factor: 4,910**
- 107)** Galletti G., De Simone G., Mazza E.M.C., Puccio S., Mezzanotte C., Bi T.M., Davydov A.N., Metsger M., Scamardella E., Alvisi G., De Paoli F., Zanon V., Scarpa A., Camisa B., Colombo F.S., Anselmo A., Peano C., Polletti S., **Mavilio D.**, Gattinoni L., Boi K.S., Youngblood B.A., Jones R.E., Baird D.M., Gostick E., Llewellyn-Lacey S., Ladell Price D.K., Chudakov D.M., Newell E.W., Casucci M. and Lugli E.\*  
 Two subsets of stem-like CD8<sup>+</sup> memory T cell progenitors with distinct fate commitments in humans  
*Nature Immunology* 2020 Oct 12. doi: 10.1038/s41590-020-0791-5. Online ahead

of print. **Impact Factor: 20.479**

- 108)** Polidoro M.A., Mikulak J., Cazzetta V., Lleo A., **Mavilio D.**, Torzilli G. and Donadon M.  
Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells  
*World Journal of Gastroenterology* 2020 Sep 7;26(33):4900-4918.  
**Impact Factor: 3.665**
- 109)** Valsecchi M., Cazzetta V., Oriolo F., Lan X., Piazza R., Saleem M.A., Singhal P.C.,  
**Mavilio D.**, Mikulak J. and Aureli M.  
APOL1 polymorphism modulates sphingolipid profile of human podocytes.  
*Glycoconjugate Journal* 2020 Sep 11. doi: 10.1007/s10719-020-09944-w. Online ahead  
of print. **Impact Factor: 2.197**
- 110)** Carezza C., Franzese S., Calcaterra F., **Mavilio D.** # and Della Bella S. #\*  
Comprehensive phenotyping of dendritic cells in cancer patients by flow cytometry  
*Cytometry, Part A*, 2020 Oct 24. doi: 10.1002/cyto.a.24245. Online ahead of print.  
**Impact Factor: 3.124**
- 111)** Pesce S. #, Trabanelli S. #, Di Vito C. #, Greppi M., Obino V., Guolo F., Minetto P.,  
Bozzo, Calvi M., Zaghi E., Candiani S., Lemoli R.M., Jandus C. #, **Mavilio D.** # and  
Marcenaro E. #\*\*  
Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes  
*Cancers (Basel)*. 2020 Nov 25;12(12):E3504 - **Impact Factor: 6.126**
- 112)** Giaccone L, Faraci DG, Butera S, Lia G, Di Vito C, Gabrielli G, Cerrano M, Mariotti J,  
Dellacasa C, Felicetti F, Brignardello E, **Mavilio D** and Bruno B.  
Biomarkers for acute and chronic graft versus host disease: state of the art  
*Expert Rev Hematol*. 2021 Jan;14(1):79-96 - **Impact Factor: 2.573**
- 113)** Castagna L., Valli V., Timofeeva I., Capizzuto R., Bramanti S., Mariotti J., De  
Philippis C., Sarina B., Mannina D., Giordano L., De Paoli F., van Beek J.J.P.,  
Zaghi E., Calvi M., Di Vito C., **Mavilio D.**, Crocchiolo R. and Lugli E..  
Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after  
haploidentical transplantation with post-transplantation cyclophosphamide in  
patients with hematological malignancies.  
*Biol Blood Marrow Transplant (now Transplantation and Cellular Therapy)*  
March 11 2021 - doi.org/10.1016/j.jtct.2021.03.010. **Impact factor: 3.853**
- 114)** Bachetti T., Rosamilia F., Bartolucci M., Santamaria G., Mosconi M., Sartori S., De  
Filippo M.R., Di Duca M., Obino V., Avanzini S., **Mavilio D.**, Candiani S., Petretto  
Andrea, Pini Prato A., Ceccherini I and Lantieri F.  
The OSMR gene is involved in Hirschsprung Associated Enterocolitis susceptibility  
through an altered downstream signaling  
*International Journal of Molecular Sciences*, March 2021 (in press).  
**Impact factor: 4.556**
- 115)** Cazzetta V., Franzese S., Carezza C., Della Bella S., Mikulak : and Mavilio D.\*  
Natural Killer–Dendritic Cell Interactions in Liver Cancer: Implications for  
Immunotherapy.  
*Cancers (Basel)*. 2021 (in press). **Impact Factor: 6.126**

\* Corresponding Author / # Shared Authorship

Total Raw Impact Factor: 710,494 - Research Gate RG Score: 42,18

Total H Index: 34 (Scopus) – 40 (Google Scholar) / i10 Index: 87 (Google Scholar)

Total Number of Citations: 5069 (Scopus) – 7190 (Google Scholar)

(Updated on May 6, 2021)

## b) Books

### 1) *Natural Killer Cells, Basic Science and Clinic Application*

First Edition 2010

Chapter 36: "Natural killer cells and human immunodeficiency virus" by **Domenico Mavilio**, Anne Hosmalin, Daniel Scott-Algara.

Editor: Academic Press, Elsevier and Macmillan Publishing, Oxford, UK

## 2) *T cell differentiation – Methods and Protocols*

Chapter: FACS analysis of memory T lymphocytes by Enrico Lugli, Veronica Zanon, **Domenico Mavilio D.** and Roberto A.

Methods in Molecular Biology 2017;1514:31-47.

Editor: Springer International Publishing

## Research Supports/Grants

### a) *As Principal Investigator*

- 1) September 2003 – September 2004 Intramural Program of NIAID/NIH, USA.  
Project Number Z01 AI000958-01 LIR - Amount Funded: \$ 130.000,00 (completed).
- 2) September 2004 – September 2005 Intramural Program of NIAID/NIH, USA.  
Project Number Z01 AI000958-01 LIR - Amount Funded: \$ 130.000,00 (completed).
- 3) September 2005 – September 2006 Intramural Program of NIAID/NIH, USA.  
Project Number Z01 AI000958-01 LIR - Amount Funded: \$ 130.000,00 (completed).
- 4) September 2006 – September 2007 Intramural Program of NIAID/NIH, USA.  
Project Number Z01 AI000958-01 LIR - Amount Funded: \$ 130.000,00 (completed).
- 5) September 2007 – September 2008 Intramural Program of NIAID/NIH, USA.  
Project Number Z01 AI000958-01 LIR - Amount Funded: \$ 130.000,00 (completed).
- 6) January 2009 - December 2011 / Italian Ministry of Health: "Ricerca Finalizzata 2007".  
Proposal ICH-2007-643769: "Characterization of phenotype, functions and trafficking of Natural Killer cells in human liver: an unknown paradigm in human physiopathology"  
Amount Funded: € 290.000,00 (completed).
- 7) January 2010 - December 2011 / Intramural Research Funding of Istituto Clinico Humanitas.  
Proposal 20090917: "Natural Killer cells and autoimmune arthritis: identification of novel biomarkers for an early diagnosis and clinical follow-up."  
Amount Funded: € 40.000,00 (completed).
- 8) March 2008 – March 2012 Marie Curie International Reintegration Grants, European Union  
Proposal 204188: "Role of innate immunity in the pathogenesis of autoimmune diseases (Acronym: RIISPAD) - Amount Funded: € 100.000,00 (completed).
- 9) January 2010 - December 2012 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
Proposal IG 9104: "Role of Natural Killer cells in the lymphomagenesis associated to autoimmune diseases" (Amount Funded: € 270.000,00).  
**PI.: Domenico Mavilio (completed)**
- 10) January 2011 – June 2013 / Italian Ministry of Health: "Ricerca Finalizzata - Bando AIDS".  
Proposal RF-ICH-2009-1299677 "Siglec-7 expression on Natural Killer cells distinguishes dysfunctional cell subsets during HIV-1 infection: a potential cellular biomarker capable of identifying the clinical stages of disease and the effectiveness of antiretroviral therapy" - Amount Funded: € 98.000,00 (completed).
- 11) January 2011 – December 2014 / Italian Ministry of Health: "Ricerca Finalizzata - Bando Giovani Ricercatori 2008".  
Proposal GR-2008-1135082: "Hirschsprung's disease as a model of neuro-immune dysfunctions in the gut: role of RET proto-oncogene in the correct development and maintenance of microbial homeostasis" - Amount Funded: € 585.000,00 (completed).
- 12) January 2014 – January 2015 / Fondazione Umberto Veronesi

- 2014 Post-doctoral Fellowships: “Role of Natural Killer cells in the colorectal carcinoma liver metastasis” (Amount Funded: € 27.000,00).  
Assigned to Kelly Hudspeth, Ph.D. (**Supervisor: Domenico Mavilio**) (completed).
- 13)** January 2013 – December 2015 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
AIRC fellowship AIRC 13833: “Improving adoptive T cell immunotherapy for cancer Through T memory stem cell properties” (Amount Funded: € 60.000,00).  
Assigned to Alessandra Roberto, Ph.D. Student (**Supervisor: Domenico Mavilio**) (completed)
- 14)** January 2013 – December 2015 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
AIRC fellowship 13678: “Endothelial progenitor cells in the pathogenesis of Kaposi's Sarcoma” (Amount Funded: € 60.000,00).  
Assigned to Francesca Calcaterra, Ph.D. Student (**Supervisor: Domenico Mavilio**) (completed).
- 15)** January 2014 - December 2015 / Intramural Research Funding of Istituto Clinico Humanitas.  
Proposal 2014: “Natural Killer and T cell immune-restitutions in haploidentical bone marrow transplantation: implications for the establishment of novel cellular biomarkers and for the development of adoptive cell transfer therapies.”.  
Amount Funded: € 80.000,00 (completed).
- 16)** February 2015 – January 2016 / Fondazione Umberto Veronesi  
2015 Post-doctoral Fellowships : “Role of Tumor-infiltrating Liver-resident Natural Killer Cells in the Control and Prognosis of Colorectal Carcinoma Metastases of the Liver” (Amount Funded: € 27.000,00).  
Assigned to Kelly Hudspeth, Ph.D. (**Supervisor: Domenico Mavilio**) (completed)
- 17)** January 2014 – December 2016 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
AIRC fellowship AIRC 14910: “Role of Natural Killer cells in the increased risk of lymphomagenesis in salivary glands of Sjogren's syndrome patients” (Amount Funded: € 60.000,00).  
Assigned to Elena Pontarini, Ph.D. Student (**Supervisor: Domenico Mavilio**) (completed).
- 18)** January 2014 - December 2017 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
Proposal IG 14687: "NCR+ V $\alpha$ 1 T cells: role of a newly disclosed cell T subset in the pathogenesis and cure of cancer " - Amount Funded: € 290.000,00 (completed).
- 19)** April 2016 – March 2019 / Cariplo Foundation  
Proposal 2015-0603 “Impact of donor cellular senescence in the immune-reconstitution and clinical outcome of elderly patients affected by hematologic malignancies and undergoing allogeneic hematopoietic stem cell transplantation”.  
Amount Funded: € 350.000,00 (completed).
- 20)** April 2017 – March 2020 / Fondazione Umberto Veronesi  
2017, 2018 and 2019 Post-doctoral Fellowships “Impact of viral infections on NK cell reconstitution after allogeneic bone marrow transplantation to cure patients affected by hematologic malignancies”. Amount Funded: € 81.000,00).  
Assigned to Clara Di Vito, Ph.D. (**Supervisor: Domenico Mavilio**) (completed).
- 21)** January 2018 – December 2020 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
AIRC fellowship 20870: “Impact of viral infection on NK cell reconstitution after allogeneic bone marrow transplant to cure hematologic tumors”. (Amount Funded: € 75.000,00).  
Assigned to Elisa Zaghi, Ph.D. Student (**Supervisor: Domenico Mavilio**) (active).
- 22)** September 2018 – August 2021 / Italian Ministry of Health: “Bando Ricerca Finalizzata”.  
Proposal PE-2016-02363915: “Role of auto-reactive hepatic Natural Killer cells in the pathogenesis of Primary Biliary Cholangitis.”  
Amount Funded: € 450.000,00 (active).
- 23)** January 2019 - December 2024 / Associazione Italiana per la Ricerca sul Cancro (AIRC).

Proposal IG 21567: " Targeting allo-reactive Natural Killer cell immune reconstitution in Hematologic tumors after bone marrow transplant "  
Amount Funded: € 578.000,00 (active).

**24)** March 2019 - February 2020 / Intramural Program of Humanitas Research Hospital.  
Proposal 2019: " At the borders between immune tolerance and autoimmunity: disclosing the mechanisms boosting the expansion of auto-reactive Natural Killer cells in Primary Biliary Cholangitis".  
Amount Funded: € 71.500,00 (active).

**25)** January 2020 – December 2020 / Fondazione Umberto Veronesi  
2020 Post-doctoral Fellowships "Targeting tumor infiltrating dendritic cells for implementing and monitoring immunotherapeutic approaches in high grade gliomas".  
(Amount Funded: € 30.000,00).  
Assigned to Francesca Calcaterra, Ph.D. (**Supervisor: Domenico Mavilio**) (active).

**26)** October 2020 – April 2021 / Fondazione Cariplo-Fondazione Umberto Veronesi  
Targeting acute immune responses and aberrant inflammation to improve the clinical outcome of elderly SARS-Cov-2 infected patients (IMMU-COV-AGING).  
(Amount Funded: € 136.050,00).

**27)** January 2020 - December 2021 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
AIRC fellowship 25491: NK-DC crosstalk in glioma microenvironment explored by single-cell RNAseq". (Amount Funded: € 25.000,00).  
Assigned to Claudia Carena, Ph.D. (**Supervisor: Domenico Mavilio**) (active).

**Total of competitive funds awarded as Principal Investigator:**  
**\$ 650.000,00 in the United States at the National Institutes of Health**  
**€ 3.783.050,00 in Italy at the Unit of Clinical and Experimental Immunology**

#### **b) As Co-Principal Investigator**

- 1)** June 2010 – June 2011 / Oslo University, Norway.  
Proposal "Functional relevance of Natural Killer cells in the pathogenesis of primary sclerosing cholangitis" (Amount Funded: € 30.000,00).  
**Co-P.I.s:** *Pietro Invernizzi and Domenico Mavilio (completed)*
- 2)** January 2011 – June 2013 / Italian Ministry of Health: "Ricerca Finalizzata - Bando AIDS".  
Proposal RF-ICH-2009-1304134: "HIV-1 interactions with primary human podocytes: characterization of the cellular and molecular mechanisms involved in the establishment of a viral reservoir in the kidney." (Amount Funded: € 49.000,00).  
P.I.: Joanna Mikulak - **Co-PI.: Dr. Domenico Mavilio (completed)**
- 3)** January 2011 – December 2014 / Associazione Italiana per la Ricerca sul Cancro (AIRC).  
Proposal MFAG 10607: "Treatment of human melanoma xenograft by a potent, newly identified human CD8+ memory T cell subset". (Amount Funded: € 150.000,00).  
P.I.: Enrico Lugli – **Co-PI.: Dr. Domenico Mavilio (completed)**
- 4)** February 2011 – February 2015 / Marie Curie International Reintegration Grants, European Union  
Proposal 249249 : Characterization of NK cell distributions and functions in human tissues in HIV -1 pathogenesis (Acronym: CNKHIV) (Amount Funded: € 100.000,00).  
P.I.: Joanna Mikulak – **Co-PI: Dr. Domenico Mavilio (completed)**
- 5)** August 2012 – August 2016 / European Union, Marie Curie International Reintegration Grant.  
Progetto FP7-PEOPLE-2012-CIG 322093: "Improving adoptive T cell transfer immunotherapy for cancer with T memory stem cells (STEMIMMUNE). (Amount Funded: € 100.000,00).  
P.I.: Dr. Enrico Lugli - **Co-PI.: Dr. Domenico Mavilio (completed)**
- 6)** January 2013 – December 2016/ Cariplo Foundation  
Proposal 2012-0683 "Contribution of T memory stem cells to successful immune recovery in humans following bone marrow transplantation" (Amount Funded: €

525.000,00).

P.I.: Enrico Lugli – **Co-PI.: Domenico Mavilio** (completed)

- 7) January 2015 – December 2017 / Italian Ministry of Health: “Bando Giovani Ricercatori”.  
Proposal GR-2011-02347324: “Generating stem cell-like T cells to improve immune reconstitution and anti-tumor immunity.” (Amount Funded: € 342.000,00).  
P.I.: Enrico Lugli – **Co PI.: Domenico Mavilio** (completed)
- 8) January 2015 – December 2018 / Italian Ministry of Health “Bando Giovani Ricercatori”.  
Proposal GR-2011-02347381: “Interactions of genotype, phenotype, local immune system and microbiologic environment in the pathogenesis of Hirschsprung's disease associated enterocolitis.” (Amount Funded: € 340.000,00).  
P.I.: Alessio Pini Prato – **Co P.I.: Domenico Mavilio** (completed)
- 9) January 2016 – December 2019 - Italian Ministry of Health: “Bando Giovani Ricercatori”.  
Proposal GR-2013- 02359185: “CD45RA-depleted donor lymphocyte infusions for the prevention of infections in patients affected by hematological malignancies after haploidentical stem cell transplantation and post-transplant cyclophosphamide.” (Amount Funded: € 382.000,00).  
P.I.: Roberto Crocchiolo – **Co P.I.:** Luca Castagna, Enrico Lugli and **Domenico Mavilio** (completed)
- 10) August 2016 – January 2020 / Italian Ministry of Health: “Bando Giovani Ricercatori”.  
Proposal GR-2013- 02356522: “Natural killer cells and macrophages cross-talk in the pathogenesis of HIV-1 infection.” (Amount Funded: € 382.000,00).  
P.I.: Benedetta Savino – **Co P.I.:** Alessandra Roberto, Massimo Locati and **Domenico Mavilio** (completed)
- 11) July 2019 – June 2022 / Italian Ministry of Health: “Bando Ricerca Finalizzata”.  
Proposal RF-2016-02364099: “Infusion of anti-NKG2A monoclonal antibody to improve Natural Killer cell allo-reactivity and clinical outcome in patients affected by hematological malignancies after unmanipulated haploidentical stem cell transplantation and post transplant cyclophosphamide.” (Amount Funded: € 434.025,00).  
**P.I.:** Luca Castagna - **Co P.I.:** Clara Di Vito, Emanuela Marcenaro and **Domenico Mavilio** (closed)
- 12) September 2019 – August 2022 / Italian Ministry of Health: “Bando Ricerca Finalizzata”.  
Proposal GR-2018-12365520: “Role of endothelial dysfunction in the pathogenesis of unprovoked venous thromboembolism.” (Amount Funded: € 450.000,00).  
**P.I.:** Marco Paolo Donadini - **Co P.I.:** Francesca Calcaterra and **Domenico Mavilio** (active)
- 13) September 2020 – August 2020 / Italian Ministry of Health: “Bando Covid-19”.  
Proposal COVID-2020-12371640-Humanitas: “Innate and Adaptive Immune Responses in COVID 19: from mechanisms to patients ” (Amount Funded: € 783.378,36).  
**P.I.:** Alberto Mantovani - **Co P.I.:** Maria Rescigno, **Domenico Mavilio**, Sergio Abrignani, Alessandro Rambaldi (active)
- 14) June 2021 - August 2024 / Cariplo Foundation  
Proposal 2020-3606 “Impact of endothelial dysfunctions in the pathogenesis of antiphospholipid syndrome-associated thrombosis”.  
Amount Funded: € 250.000,00 (completed).  
**P.I.:** Francesca Calcaterra - **Co P.I.:** Marco Paolo Donadini, Corrado Lodigiani and **Domenico Mavilio** (active)

**Total of competitive funds awarded as Co-Principal Investigator:  
€ 4.317.403,36 in Italy at the Unit of Clinical and Experimental Immunology**

**Total of direct and indirect funds awarded to Prof. Mavilio: \$ 650.000,00  
€ 8.100.453,36**

**Awards** 1) Travel Award for the 9th Meeting of The Society for Natural Immunity



Kauai, Hawaii, USA. November 4-8, 2005.

- 2) Award for the best poster presentation at 4th International Conference on Innate Immunity. Corfu', Greece. June 4-9. 2007.
- 3) Performance Award. National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA June, 6, 2007.
- 4) Performance Award. National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA, June, 6, 2008
- 5) Awarded as "Second Best Italian Senior Investigator under 40 years old" by Associazione Italiana di Colture Cellulari (AICC) Firenze, Dicembre 3 2009.

#### Participation in Clinical Trials

- 1) 2010-2011: Novartis – Live Study

#### Organized Meeting

- 1) Workshop SIICA (Italian Society of Clinical Immunology and Allergology) "Innate immunity in the pathogenesis of immune-mediated human diseases". Conference Centre of Humanitas Research Hospital, Rozzano (Milano), Italy. 2-4 November 2010  
**Chairman: Domenico Mavilio**
- 2) Workshop SIICA (Italian Society of Clinical Immunology and Allergology) "2nd Conference of translational medicine on pathogenesis and therapy of immune-mediated diseases". Conference Centre of Humanitas Research Hospital, Rozzano (Milano), Italy. 5-7 November 2012  
**Chairman: Domenico Mavilio**
- 3) Workshop SIICA (Italian Society of Clinical Immunology and Allergology) "3rd Conference of translational medicine on pathogenesis and therapy of immune-mediated diseases". ([www.translationalimmunology.it](http://www.translationalimmunology.it)) Conference Centre of Humanitas Research Hospital, Rozzano (Milano), Italy. 29-30 September – 1 October 2014  
**Chairman: Domenico Mavilio**
- 4) "4<sup>th</sup> Conference of translational medicine on pathogenesis and therapy of immune-mediated diseases". ([www.translationalimmunology.it](http://www.translationalimmunology.it)) Conference Centre of the University of Palermo, Italy. March 27-29 2017  
**Chairmen: Francesco Dieli and Domenico Mavilio**
- 5) "5<sup>th</sup> Conference of translational medicine on pathogenesis and therapy of immune-mediated diseases". ([www.translationalimmunology.it](http://www.translationalimmunology.it)) Conference Centre of the University of Milan, Italy. May 16-18 2019  
**Chairmen: Francesco Annunziato, Massimo Locati and Domenico Mavilio**

#### Oral Presentations, Seminars, Lectures

- 1) **D. Mavilio**, D., Dignetti P., Ferrera L., Colombara M., Quaglia R., Scordamaglia A., Mincarini M., De Maria A. e G.W. Studio pilota di immunoterapia adiuvante con r-IL 2 sottocute in corso di Tuberculosis Polmonare Cronica Canonica 1° Congresso Nazionale – Unione Italiana per la Pneumologia. Catania 8-11 Novembre 2000.  
(Meeting. Selected Speaker)
- 2) **Mavilio D.**, Canonica G.W. Sistema Immunitario e Affezioni Respiratorie nell'Attività Sportiva - 35° Congresso Nazionale AIPO, Firenze 6-9 Novembre 1999.  
(Meeting. Selected Speaker)
- 3) Natural Killer cells in HIV-1 Infection.  
Novel Markers of HIV-1 Pathogenesis: Future Clinical Biomarkers?  
Washington DC, USA, May 15 2004.  
(Meeting. Invited by Dr. Susan Plaeger, Ph.D.)
- 4) NK cell dysfunctional activities during HIV-1 Infection.

Department of Microbiology and Immunology, Vanderbilt University School of Medicine. Nashville Tennessee (USA), October 12 2004.  
(Seminar. Invited by Prof. Derya Unutmaz)

- 5) Activating and Inhibiting NK cell Receptors in HIV-1 Infection.  
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute. Frederick, Maryland (USA), February 12 2005.  
(Seminar. Invited by Dr. George Pavlakis).
- 6) Dendritic Cells and Natural Killer Cells in HIV-1 infected viremic individuals.  
International AIDS Society (IAS), Rio De Janeiro, Brazil. July 24-27, 2005.  
(Meeting. Selected Speaker)
- 7) Innate Immunity and HIV-1 Infection.  
AIDS Immunopathogenesis Section Unit, San Raffaele Scientific Institute. Milano (Italy), September 26 2005.  
(Seminar. Invited by Prof. Guido Poli, M.D.)
- 8) HIV-1 Infection and Innate Immunity: Disrupted cross-talk between NK cells and DCs and the role of the CD56-/CD16+ NK cell subset. 9th Meeting of The Society for Natural Immunity, 2005, Kauai, Hawaii, USA. November 4-8 2005.  
(Meeting. Selected Speaker)
- 9) Interactions between NK cells and Dendritic Cells during HIV-1 Infection.  
Servizio di Virologia, IRCCS Policlinico San Matteo and Università degli Studi di Pavia. Pavia (Italy), December 15 2005  
(Seminar. Invited by Prof. Mario Mondelli)
- 10) Innate Immunity in HIV infection; paradigm for protection or targets for ambush?  
Fondazione Andrea Cesalpino, Dipartimento di Medicina Interna, Università degli Studi di Roma La Sapienza. Rome (Italy), December 12 2005  
(Seminar. Invited by Prof. Vincenzo Barnaba)
- 11) Innate Immunity and HIV-1 Infection.  
Department of Pediatrics, University of Brescia  
Brescia (Italy), February 16 2006  
(Seminar. Invited by Prof. Alessandro Plebani, M.D.)
- 12) Dichotomous effect of HIV-1 viremia on Inhibitory and Activating NK Cell Receptors.  
Receptor Cell Biology Section - Laboratory of Allergic Diseases, NIAID, NIH  
Bethesda, Maryland, USA, May 26 2006  
(Seminar. Invited by Dott. John Coligan)
- 13) Role of Natural Killer Cells in HIV-1 Infection.  
Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari. Bari, Italy, June 25 2006  
(Seminar. Invited by Prof. Franco Dammacco, M.D.)
- 14) Role of Innate Immunity in the Pathogenesis of HIV-1 Infection: from Basic Research to Clinic.  
Laboratory of Experimental Immunology, National Cancer Institute.  
Frederick, Maryland, USA, September 15 2006  
(Seminar. Invited by Stephen K. Anderson, Ph.D)
- 15) Innate Immune Response and HIV-1 Infection: "Defective Interactions between Natural Killer Cells and Dendritic Cells  
Department of Immunology and Microbiology, Rush Medical School.  
Chicago, Illinois, USA, February 2 2007  
(Seminar. Invited by Prof. Edward Barker, Ph.D)
- 16) Escape of HIV-1 from Innate Immune Response  
Humanitas Research Hospital  
Milano, Italy, April 14 2007  
(Seminar. Invited by Prof. Alberto Mantovani, M.D.)

17) Innate Immune Response in the Pathogenesis of HIV-1 Infection

- Istituto di immunologia Clinica, Università degli Studi di Padova  
Padova, Italy, April 16 2007  
(Seminar. Invited by Prof. Gianpietro Semenzato, M.D.)
- 18)** Role of Innate Immune System in the pathogenesis of HIV-1 infection  
Pasteur Institute. ANRS AC31. Paris, France, April 22 2007  
(Meeting. Invited by Prof. Eric Vivier, D.V.M – Ph.D.)
- 19)** Lack of Innate Immune Responses in HIV-1 infection  
King's College Medical School. London, UK, July 16 2007  
(Seminar. Invited by Prof. Mike Malim, Ph.D.)
- 20)** Disrupted interactions between Dendritic Cells and Natural Killer Cells in HIV-1 infected viremic individuals. International AIDS Society (IAS), Rio De Janeiro, Brazil. July 24-27, 2007.  
(Meeting. Selected Presentation)
- 21)** Innate immune response in the clearance of autologous HIV-1 infected CD4+ T cells ex vivo. AIDS Immunopathogenesis Section Unit, San Raffaele Scientific Institute. Milano (Italy). July 16 2007  
(Seminar. Invited by Prof. Guido Poli, M.D.)
- 22)** Escape of HIV-1 from Innate Immune Responses  
Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Varese, Italy. December 12 2007  
(Seminar. Invited by Prof. Roberto S. Accolla, M.D.)
- 23)** HIV-1 and Innate Immune Responses.  
Wistar Institute, Laboratory of Immunopathogenesis, Philadelphia, PA, USA  
February 15 2008  
(Seminar. Invited by Prof. Luis Montaner, Ph.D.)
- 24)** Role of NK cells in the eradication of HIV-1 infected cells.  
Department of Immunology, Institute Cochin, INSERM Unit 567, Paris, France  
April 19 2008  
(Seminar. Invited by Prof. Anne Hosmalin, M.D., Ph.D.)
- 25)** NK cell-mediated lysis of endogenously infected ad autologous CD4+ T cells from HIV-1 infected patients.  
6th National Conference of Italian Society of Immunology (SIICA), Rome, Italy  
June 18 2008 (Invited by Prof. Silvano Sozzani, M.D., Ph.D)
- 26)** NK cells and clearance of HIV-1 infected autologous cells.  
5<sup>th</sup> Innate Immunity Conference, Crete, Greece. June 21 2008  
(Meeting. Invited by Prof. John Lambris, Ph.D.)
- 27)** Role of Natural Killer Cells in the Physiopathology of Immunological Diseases.  
XLV Meeting of the Italian Society of Rheumatology, Venice, Italy. October 16 2008  
(Meeting. Invited by Prof. C. Montecucco)
- 28)** Rôle des cellules dendritiques dans la Physiopathologie de l'infection par VIH  
Role of dendritic cells in the pathogenesis of HIV infection  
Pasteur Institute. ANRS AC31. Paris, France, April 15 2009  
(Meeting. Invited to Chair by Prof. Anne Hosmalin, M.D., Ph.D.)
- 29)** Role of NK cells in HIV infection.  
ICAR - Italian Conference on AIDS and Retroviruses. May 15-17 2009, Milan, Italy  
(Meeting. Invited by Prof. Mauro Moroni, M.D.)
- 30)** NK cell phenotypic and functional characterization in HIV-1 infection.  
GRS, Pasteur Institute. Paris, France, June 26 2009.  
(Meeting. Invited by Dott. Gianfranco Pancino, M.D.)
- 31)** European Congress of Immunology, Berlin. Germany. September 12-15, 2009  
(Meeting. Invited to Chair by Prof. Reinhold E. Schmidt)
- 32)** HIV-1 escape from innate immune responses.

- 2009 Tri-Society Annual Conference of the Society for Leukocyte Biology, International Cytokine Society, and the International Society for Interferon and Cytokine Research, Lisbon, Portugal, October 18-21, 2009  
(Meeting. Invited by Prof. Luis Montaner, Ph.D.)
- 33)** NK cells in HIV-1: recognition and escape.  
Lecture Course - Host-pathogen interaction: recognition and escape.  
University of Milan. Milan, October 26-27th 2009, Humanitas Research Hospital, Rozzano (MI)  
(PhD program of University of Milan. Invited by Prof. Massimo Locati, M.D.)
- 34)** Natural Killer cells in the clinical care of HIV-1 infection.  
Annual Meeting of Italian Cell Culture Society (AICC).  
Awarded as "Second Best Italian Senior Investigator under 40 years old".  
Florence, Italy, Dicembre 2-4 2009.  
(Meeting. Invited by Prof. Augusto Pessina, Chair of the AICC society)
- 35)** Natural Cytotoxicity Receptors: new insights on their role in the context of  $\gamma/\delta$  T cell immune responses.  
Department Pathology and Immunology, Washington University, St. Louis, Missouri, USA, June 12 2011  
(Seminar. Invited by Prof. Marco Colonna)
- 36)** Innate immune receptors and interactions with pathogens: from HIV-1 infection to pathogen recognition.  
Department of Immunology, University of Connecticut, Hartford, Connecticut, USA  
June 14 2011 (Seminar. Invited by Prof. Juan Salazar)
- 37)** Natural Killer cells in the physiopathology of inflammatory and autoimmune diseases"  
Autoinflammatory Days Symposium –December 12/13 2011, Padova  
(Meeting – Invited by Prof. Leonardo Punzi)
- 38)** Natural Killer cell physiology and physiopathology  
Ph.D. program of Molecular Biology, December 14 2011, Istituto Europeo di Oncologia (IFOM/IEO), Milano, Italia  
(Lecture Course for PhD Students. Invited by Prof. Maria Rescigno)
- 39)** Natural Cytotoxicity Receptors: new insights on their role in the context of tumor and HIV-1 pathogenesis.  
New York University Medical School, NY, USA - April 23 2012 (Seminar:  
Invited by Prof. Derya Unutmaz).
- 40)** Natural Cytotoxicity Receptors: new insights on their role in the context of  $\gamma/\delta$  T cell responses.  
Wistar Institute and School of Medicine of University of Pennsylvania, Philadelphia, PA, USA – April 25 2012  
(Lecture: Invited by Prof. Luis Montaner)
- 41)** Role of newly discovered subset of NCR<sup>pos</sup>  $\gamma/\delta$  T cells in the pathogenesis of human diseases.  
Medical School of Cardiff University, Cardiff, Wales, United Kingdom, November 16 2012  
(Lecture: Invited by Prof. David Price)
- 42)** From HIV-1 Infection to mucosal immunity and autoimmunity: the case of innate immune responses as an example of translational and transversal experimental immunology  
National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA. November 30, 2012.  
(Seminar. Invited by Dott. Juan Rivera)
- 43)** International Workshop "HIV cure and eradication: a feasible option?"  
Palazzo delle Stelline, Milan, Italy. January 24-25, 2013 – Faculty and Chairman  
(Meeting. Invited by Prof. A. Lazzarin)
- 44)** HIV-1 escape from immune responses

Italian Workshop “Immunologia Clinica dell’Infezione da HIV: Progressi e Nuove Frontiere”. Villa Stella Maris, Ancona, Italy. February 8-9, 2013  
(Meeting. Invited by Dott. Luca Butini)

- 45)** From HIV-1 infection to mucosal immunity: the case of NK cell responses as an example of translational experimental immunology.  
Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and London School of Medicine and Dentistry, London, UK  
July 22, 2013 (Seminar. Invited by Prof. Michele Bombardieri)
- 46)** Role of Siglec-7 and HIV-1 pathogenesis.  
What will it take to achieve an AIDS free world?  
November 3-5, 2013, San Francisco, CA, USA (Meeting. Selected Abstract)
- 47)** From HIV-1 infection to mucosal immunity: the case of NK cell responses as an example of translational experimental immunology.  
Dipartimento di Patologia Generale, Università di Verona  
November 15, 2013 (Seminar. Invited by Prof. Cassatella)
- 48)** Siglec-7 and HIV-1 pathogenesis.  
Conference on Retroviruses and Opportunistic Infections (CROI)  
March 3-6, 2014, Boston, MA, USA (Meeting. Selected Abstract)
- 49)** From HIV-1 infection to mucosal immunity: the case of NK cell responses as an example of translational experimental immunology.  
Division of Immunology, Department of Pediatrics, Children Hospital, Cincinnati, OH, USA  
March 8, 2014 (Seminar. Invited by Prof. Senad Divanovich).
- 50)** NK cell in the pathogenesis of Sjogren Syndrome.  
Adeno-associated Virus Biology Sections, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA  
March 10, 2014 (Seminar. Invited by Dr. Jay A. Chiorini).
- 51)** Hirschsprung’s Diseases and Microbiome.  
Genetic Disease Research Branch, National Human Genome Research Institute of National Institutes of Health, Bethesda, MD, USA  
March 11, 2014 (Seminar. Invited by Dr. William J. Pavan).
- 52)** Natural Killer cell as effector and regulatory lymphocytes  
Ph.D. program of Molecular Biology (SEMM/SIPOD), May 27, 2014, European institute of Oncology, (IFOM/IEO), Milan, Italy  
(Lecture Course for PhD Students. Invited by Prof. Maria Rescigno)
- 53)** Innate immunity and priming of optimal immune responses in human physiology and physiopathology.  
June 26, 2014. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA  
(Seminar. Invited by Dr. Manfred Bohem)
- 54)** NK cells and macrophages in HIV-1 infection: a rendezvous that deserves to be better defined.  
July 8, 2014. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. (Seminar. Invited by Dr. Genoveffa Franchini).
- 55)** T cell subset immune-reconstitution and immunological memory in haplo-identical hematopoietic stem cell transplants  
August 29, 2014. Third symposium “ImmunoThérapie Allogénique du Cancer”  
August, 29<sup>th</sup> - 30<sup>th</sup>, Paris, France  
(Meeting. Invited by Dr. Didier Blaise).
- 56)** Cross talk between NK cells and macrophages : a key rendezvous in human physiology and physiopathology.  
November 6<sup>th</sup> 2014. Medical School, University of Palermo, Italy  
(Seminar. Invited by Prof. Francesco Dieli).
- 57)** Immune reconstitutions in haplo-identical hematopoietic stem cell transplants

- November 21<sup>st</sup>, 2014. Department of Hematology, Marseille Cancer Center, Institut Paoli Calmettes, Marseille, France. (Seminar. Invited by Dr. Daniel Olive)
- 58)** Immune reconstitutions in haplo-identical hematopoietic stem cell transplants  
December 2 2014. Department of Oncology Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD, USA  
(Seminar. Invited by Dr. Leo Luznik).
- 59)** Cellular mechanisms of T cell reconstitution following haploidentical transplantation.  
December 4 2014. Haploidentical transplantation meeting 2014 - Intercontinental Hotel, San Francisco, CA, USA  
(Meeting. Invited by Dr. Stefan Ciurea).
- 60)** Rendezvous between NK cells and macrophages in the link between adaptive and innate immune responses.  
January 14 2015. Università Vita Salute, San Raffaele Medical School, Milan, Italy  
(Seminar. Invited by the board of the Ph.D Program in Immunology).
- 61)** NK cells and macrophages in the link between adaptive and innate immune responses.  
May 5 2015. Institute for Research in Biomedicine Ph.D. student retreat  
Weggis, Lucerne, Switzerland  
(Seminar and mentor for the Ph.D, students. Invited by Prof. Antonio Lanzavecchia).
- 62)** Immune-reconstitutions and immunological memory in haplo HSCT  
May 29, 2015. Advance in alternative donor stem cell transplantation: a euro-mediterranean perspective - Villa de la Méditerranée, Marseille, France.  
May 29-30, 2015  
(Meeting. Invited by Prof. Didier Blaise).
- 63)** Genetics, immunology and microbiome in the pathogenesis of enterocolitis associated to the Hirschprung diseases.  
June 12, 2015. Incontro con l'associazione dei pazienti affetti dalla Malattia di Hirschprung – CISEFm Genova, Italy. June 12-13, 2015  
(Meeting. Invited by Dr. Alessio Pini Prato).
- 64)** From HIV-1 infection to mucosal immunity: the case of NK cell responses as an example of translational experimental immunology.  
European institute of Oncology, (IFOM/IEO), Milan, Italy  
July 17, 2015 (Seminar. Invited by Dr. Federica Facciotti).
- 65)** Hepatic Natural Killer cells in the pathogenesis of Primary Biliary Cirrhosis.  
July 27, 2015. Finding the cure for PBC – The Nordic House, Reykjavik, Iceland  
July 26-29, 2015  
(Meeting. Invited by Prof. M. Eric Gershwin).
- 66)** Hepatic Natural Killer cells in autoimmune liver diseases.  
November 16, 2015 – University of California Davis, Davis, CA, USA  
(Seminar. Invited by Prof. M. Eric Gershwin).
- 67)** Interplay between NK cells and autologous macrophages in the pathogenesis of HIV-1 infections.  
November 18, 2015 – University of California San Francisco, CA, USA  
(Seminar. Invited by Prof. Jay A. Levy).
- 68)** Interplay between GALT immune responses and Microbiome in Hirschsprung's Diseases  
Genetic Disease Research Branch, National Human Genome Research Institute of National Institutes of Health, Bethesda, MD, USA  
November 20<sup>th</sup>, 2015 (Seminar. Invited by Dr. William J. Pavan).
- 69)** NK cell and Organization of Tertiary Lymphoid Structures in viral induced sialadenitis.  
Adeno-associated Virus Biology Sections, National Institute of Dental and Craniofacial Research, national Institutes of Health, Bethesda, MD, USA  
November 23, 2015 (Seminar. Invited by Dr. Jay A. Chiorini).
- 70)** Rendezvous between Natural Killer cells and macrophages: present and future perspectives in the pathogenesis of human diseases.  
Ludwig Center for Cancer Research, University of Lausanne, Switzerland.  
March 8, 2016 (Seminar. Invited by prof. Pedro Romero).
- 71)** Impact of immune cell reconstitutions in the clinical outcome of haploidentical HSCT.

- European Bone Marrow Transplant (EBMT) 2016, 3-6 April, 2016, Valencia Spain  
(Meeting. Invited by Prof. Mohamad Mohty).
- 72)** NK cells in haploidentical HSCT. Present, past and futures.  
Institute Paoli-Calmettes, Marseille, France, 25 May 2016  
(Lecture. Invited by Dr. Didier Blaise).
- 73)** NK cell immune-reconstitutions in haploidentical HSCT.  
International Meeting "Allogeneic Stem Cell Transplantation and Immunotherapy in Myeloid Malignancies" - Marseille (France), 25-27 November 2016  
(Meeting. Invited by Prof. Didier Blaise).
- 74)** NK cell immune-reconstitutions in haploidentical HSCT; clinic and therapeutic implications.  
International Meeting "Haplo-2016 symposia" within the American Society of Hematology (ASH), San Diego (CA, USA), 1 December 2016  
(Meeting. Invited by Prof. Stefan Churea).
- 75)** Interplay between Natural Killer cells and macrophages: present and future perspectives in the pathogenesis of human diseases  
Georgetown University, Washington D.C. (USA), 6 December 2016  
(Seminar. Invited by Prof. Marta Catalfamo).
- 76)** Single Topic 2017 Liver Immunology, AISF - SIICA Joint International Meeting  
Conference Center of Milan Bicocca University, Milan (Italy) 16-18 March 2017  
(Chairman invited by Prof. Pietro Invernizzi).
- 77)** Disclosing the patterns of T and NK cell immune reconstitution to improve the clinical outcome of hematopoietic stem cell transplantations to cure hematologic malignancies  
Medical School of Turin University, Turin (Italy), 19 April 2017  
(Seminar. Invited by Prof. Fabio Malavasi).
- 78)** Viral infections and hematopoietic stem cell transplantations: friends or foe for the immune system?  
Annual Meeting 2017, Research Training Group 1949, University of Essen, Germany, 15-16 May 2017  
(Lecture. Invited by Prof. Mirko Trilling and Prof. Astrid Westendorf).
- 79)** From "bench to the bed side": targeting T and NK cell immune reconstitution to improve the clinical outcome of haploidentical hematopoietic stem cell transplantation in hematologic malignancies .  
Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan, 7 July 2017.  
(Lecture. Invited by Prof. Chao-Ching Huang).
- 80)** Interplay between Natural Killer cells and macrophages: present and future perspectives in the pathogenesis and cure of cancer, autoimmune and infectious diseases.  
8<sup>th</sup> Annual Joint Conference of Taiwan Graduate Institutes of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, 8 July 2017.  
(Lecture. Invited by Prof. Kuan-Chou Chen).
- 81)** Meet the Editor: Myths and Misperceptions in publishing a scientific article.  
Development of Tissue and Pathogen-specific Cellular Innate Immunity, International Symposium, Freiburg, Germany 27-29 September, 2017.  
(Talk. Invited by Prof. Philipp Henneke).
- 82)** Characterization of a novel subset of tissue-resident NKp46<sup>pos</sup> V $\alpha$ 1 intestinal intraepithelial lymphocytes playing a key role in gut immune homeostasis and in the physiopathology of colon-cancer.  
50<sup>th</sup> Annual meeting of the Society of Leukocyte Biology.  
Vancouver, Canada. 5-7 October 2017  
(Selected Talk and Chairman - Invited by Jennifer Holland).
- 83)** Characterization of a novel subset of tissue-resident NKp46<sup>pos</sup> V $\alpha$ 1 intestinal

- intraepithelial lymphocytes playing a key role in gut immune homeostasis and in the pathophysiology of colon-cancer.  
5<sup>th</sup> Annual Meeting of the International Cytokine and Interferon Society.  
Kanazawa, Japan 28 October – 2 November 2017  
(Selected Talk and Invited as JLB Editor by Prof. Kouji Matsushima).
- 84)** Targeting Natural Killer cell immune checkpoints to improve the clinical outcome of allogeneic haplo-HSCT.  
Symposia “Innovation in immuno-mediated and hematologic disorders”, Ph.D. program in immunological, hematological and rheumatologic sciences.  
Universita' La Sapienza, Rome, Italy, 18 December 2017  
(Talk. Invited by prof. Angela Gisoni).
- 85)** Characterization of a novel subset of human NKp46<sup>pos</sup> V $\alpha$ 1 intestinal gd T lymphocytes playing key roles in gut immune homeostasis and in the pathophysiology of colon cancer.  
Hospital de Mar Medical center and University Pompeu Fabra, Barcelona, Spain. 16 January 2018 - (Seminar. Invited by Prof. Miguel Lopez-Botet).
- 86)** Siglecs in HIV-1 infection: new insights both in pathogenesis and clinic.  
Beat-HIV Network Webinar – Wistar Institute, Philadelphia, PA, USA  
9 March, 2018 (Seminar – Invited by Prof. Luis Montaner).
- 87)** Haploidentical HSCT and immune-reconstitution: from the bed to the bench.....and back to clinic again.  
National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA - 13 March 2018  
(Seminar. Invited by Prof. Luigi Notarangelo).
- 88)** Haploidentical HSCT and immune-reconstitution: from the bed to the bench.....and back to clinic again.  
4<sup>th</sup> International Symposium – Advance in Allogeneic Immunotherapy: Where do we stand in 2018? Marseille, France - 20-22 April 2018.  
(Meeting. Invited by Prof. Didier Blaise).
- 89)** NK2018 – The 17<sup>th</sup> Meeting of the Society for Natural Immunity  
San Antonio, Texas, USA – May 28 – June 1 2018  
Chairman and Moderator (Meeting. Invited by Prof. Jordan Orange)
- 90)** Ian Mackay Meeting – Lugano, Switzerland 23-25 September 2018  
Breach of tolerance in PBC: the “unexpected” intrusion of Natural Killer cells.  
(Meeting. Invited by Prof. Eric Gershwin)
- 91)** Breach of tolerance in PBC: the “unexpected” intrusion of Natural Killer cells.  
Le Malattie Autoimmuni del Fegato. Bologna, 3-5 October 2018  
(Meeting. Invited by Prof. Pietro Invernizzi on behalf of Associazione Italiana per lo Studio del fegato)
- 92)** Characterization of a novel subset of tissue-resident NKp46<sup>pos</sup> V $\alpha$ 1 intestinal intraepithelial lymphocytes playing a key role in gut immune homeostasis and in the pathophysiology of colon-cancer.  
51<sup>st</sup> Annual meeting of the Society of Leukocyte Biology.  
Chandler, Arizona USA. 14-16 October 2018  
(Selected Talk and Chairman - Invited by Jennifer Holland).
- 93)** Impatto clinico dell'immuno-ricostituzione dopo trapianto haploidentico di cellule staminali ematopoietiche.  
3 Congresso Nazionale della Società Italiana di Analisi Citometrica Cellulare. Roma, 8-10 November 2018  
(Invited Talk - Invited by Prof. Francesco Buccisano).
- 94)** “Meet the JLB editor talk”.



11th SgSI Annual Symposium on Aging and Inflammation. Singapore, May 30-31 2019.  
(Invited Talk - Invited by Prof. Amit Shingal).

**95)** Impact of intraepithelial and tissue-resident  $\gamma\delta$  T cells in the gut homeostasis and pathophysiology of colon cancer  
 $\gamma\delta$  Symposium for 2799 entitled "Receiving and Translating Signals via the  $\gamma\delta$  TCR"  
Nikolaus-Fiebiger-Zentrum (NFZ), Erlangen, Germany, June 12<sup>th</sup> – 14<sup>th</sup> 2019.  
(Invited Talk - Invited by Prof. Immo Prinz and Prof. Sarina Ravens).

**96)** NK2019 – The 18<sup>th</sup> Meeting of the Society for Natural Immunity  
Luxembourg – September 30 – October 3 2019  
Chairman and Moderator (Meeting. Invited by Prof. Jacques Zimmer).

**97)** Unconventional memory NK cells following HCMV infection in haplo-HSCT.  
52<sup>nd</sup> Annual meeting of the Society of Leukocyte Biology.  
Boston, MA, USA. 14-18 November 2019  
(Selected Talk and Chairman - Invited by Jennifer Holland).

**98)** New insights and perspectives in the use of Vd1 antitumor effector-functions to develop alternative protocols of adoptive cell transfer therapies  
Gamma-Delta therapy summit. London (U.K.) September 30, 2020  
(Invited Talk).

**Updated on May the 6<sup>th</sup>, 2021**

**Domenico Mavilio, M.D, Ph.D.**

